
==== Front
Mol Cancer
Mol Cancer
Molecular Cancer
1476-4598
BioMed Central London

39223527
2095
10.1186/s12943-024-02095-8
Review
Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy
Liu Qiang 1
Guan Yujing 234
Li Shenglong slli@cmu.edu.cn
lishenglong@dlut.edu.cn
lishenglong@cancerhosp-ln-cmu.com

234
1 grid.459742.9 0000 0004 1798 5889 Department of Urology, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning 110042 China
2 grid.459742.9 0000 0004 1798 5889 Second Ward of Bone and Soft Tissue Tumor Surgery, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning 110042 China
3 The Liaoning Provincial Key Laboratory of Interdisciplinary Research on Gastrointestinal Tumor Combining Medicine with Engineering, Shenyang, Liaoning 110042 China
4 https://ror.org/023hj5876 grid.30055.33 0000 0000 9247 7930 Institute of Cancer Medicine, Faculty of Medicine, Dalian University of Technology, No.2 Linggong Road, Ganjingzi District, Dalian, Liaoning Province 116024 China
2 9 2024
2 9 2024
2024
23 18318 7 2024
18 8 2024
© The Author(s) 2024, corrected publication 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Programmed death receptor-1 (PD-1) and its ligand, programmed death ligand-1 (PD-L1) are essential molecules that are key in modulating immune responses. PD-L1 is constitutively expressed on various immune cells, epithelial cells, and cancer cells, where it functions as a co-stimulatory molecule capable of impairing T-cell mediated immune responses. Upon binding to PD-1 on activated T-cells, the PD-1/PD-L1 interaction triggers signaling pathways that can induce T-cell apoptosis or anergy, thereby facilitating the immune escape of tumors. In urological cancers, including bladder cancer (BCa), renal cell carcinoma (RCC), and prostate cancer (PCa), the upregulation of PD-L1 has been demonstrated. It is linked to poor prognosis and enhanced tumor immune evasion. Recent studies have highlighted the significant role of the PD-1/PD-L1 axis in the immune escape mechanisms of urological cancers. The interaction between PD-L1 and PD-1 on T-cells further contributes to immunosuppression by inhibiting T-cell activation and proliferation. Clinical applications of PD-1/PD-L1 checkpoint inhibitors have shown promising efficacy in treating advanced urological cancers, significantly improving patient outcomes. However, resistance to these therapies, either intrinsic or acquired, remains a significant challenge. This review aims to provide a comprehensive overview of the role of the PD-1/PD-L1 signaling pathway in urological cancers. We summarize the regulatory mechanism underlying PD-1 and PD-L1 expression and activity, including genetic, epigenetic, post-transcriptional, and post-translational modifications. Additionally, we discuss current clinical research on PD-1/PD-L1 inhibitors, their therapeutic potential, and the challenges associated with resistance. Understanding these mechanisms is crucial for developing new strategies to overcome therapeutic limitations and enhance the efficacy of cancer immunotherapy.

Graphic abstract

Keywords

Tumor immunity
PD-1
PD-L1
Regulatory mechanism
Combination therapy
issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Cancers of the urinary system, such as bladder cancer (BCa), renal cell carcinoma (RCC), and prostate cancer (PCa), pose substantial challenges in the field of oncology. BCa, which is mainly transitional cell carcinoma, occurs more frequently in men and can be classified by the degree of invasion into non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) [1–3]. The standard treatment for NMIBC usually includes transurethral resection of the bladder tumor (TURBT) along with localized therapies to reduce the risk of recurrence [4, 5]. However, NMIBC recurs locally in 60–70% of cases, with 15–40% progressing to MIBC or distant metastasis [6, 7]. Epidemiological data indicate that the incidence of BCa varies globally, with higher rates typically observed in developed countries. The primary risk factors include smoking, occupational exposure, and chronic inflammation [8]. Smoking is considered the most significant modifiable risk factor, with studies showing that smokers are more than three times as likely to develop BCa compared to non-smokers [9]. Additionally, occupational exposure to certain chemicals, such as aniline dyes, chlorides, and chemicals related to aluminum production, significantly increases the risk of developing BCa [2]. Long-term chronic bladder inflammation, urinary tract infections, and certain parasitic infections, such as schistosomiasis, are also closely associated with the development of BCa. In terms of diagnosis, cystoscopy is regarded as the gold standard for BCa diagnosis. Cystoscopy allows for direct visualization of the bladder mucosa, enabling early detection of tumor lesions and the possibility of performing biopsies to obtain pathological evidence. However, the sensitivity and specificity of cystoscopy may be limited by the size and location of the tumor. Therefore, imaging techniques play a crucial role in the diagnosis and staging of BCa. Computed tomography (CT) and magnetic resonance imaging (MRI) are particularly essential in assessing tumor invasion depth, lymph node involvement, and distant metastasis. In recent years, molecular testing techniques have increasingly been applied to the diagnosis and characterization of BCa. Ki-67, TP53, and CK20 are key biomarkers for diagnosing and predicting BCa outcomes [10]. Ki-67 indicates tumor cell growth, with higher levels suggesting more aggressive tumors and poorer prognosis. TP53 often mutates in BCa, contributing to tumor progression and therapy resistance. CK20 can identify BCa subtypes, confirming urothelial origin and providing insights into tumor differentiation and invasiveness. Besides, FGFR3 and TERT promoter mutations have been identified as key molecular markers associated with BCa [11, 12]. These markers not only aid in the early diagnosis of tumors but also provide a basis for personalized treatment strategies. Surgery, chemotherapy, immunotherapy, and targeted therapies are essential for BCa treatment. For localized BCa, transurethral resection of bladder tumors (TURBT) and radical cystectomy are primary surgical treatments that effectively control the disease [13]. However, for advanced or metastatic cases, surgery alone is insufficient, making chemotherapy the preferred supplement. Cisplatin-based regimens like MVAC and GC are commonly used and effective. Recently, PD-1/PD-L1 immune checkpoint inhibitors have shown significant success in advanced BCa, providing an alternative for patients who cannot undergo chemotherapy [14]. Additionally, targeted therapies, such as those addressing FGFR3 mutations, offer personalized options for certain bladder cancer subtypes. Combining these treatments can improve survival rates and quality of life for bladder cancer patients. However, the 5-year survival rate remains relatively low at 20–40%, with around 50% of patients developing distant metastases within 3 years and a mere 10% surviving up to 5 years [7, 15]. RCC, which accounts for 2–3% of all cancers, originates from the renal tubular epithelium. The most common subtype is clear cell renal cell carcinoma (ccRCC) [16]. RCC is frequently asymptomatic in its early stages and is often diagnosed incidentally. At the time of diagnosis, up to 30% of cases have already metastasized [17, 18]. Despite surgical resection, about 30% of organ-confined cases experience metastasis during follow-up [19, 20]. The prognosis for advanced or metastatic RCC remains bleak, with a less than 10% survival rate at 5 years post-diagnosis, compounded by resistance to conventional therapies like chemotherapy and radiotherapy [18, 21]. PCa, prevalent in the male genitourinary system, demonstrates a promising 10-year overall survival rate of 99% for early-stage localized cases due to enhanced detection and treatment strategies [22, 23]. However, up to 25% of patients experience biochemical recurrence after initial treatment, progressing to metastatic castration-resistant prostate cancer (mCRPC) [24–26]. Once advanced, the median survival period drops to 13–32 months, with a 5-year survival rate of only 15% [27, 28]. Effective management strategies for urinary system tumors remain crucial given their profound impact on patient outcomes and societal health.

Programmed death receptor-1 (PD-1) and its ligand, programmed death ligand-1 (PD-L1), are essential immune checkpoint molecules that play a pivotal role in the evasion of tumor immune responses [29]. PD-1 is a transmembrane receptor predominantly located on activated T cells, B cells, NK cells, and monocytes [30], The ligand PD-L1, primarily found on the surfaces of tumor cells, interacts with its receptor PD-1 [31]. This interaction results in the suppression of T cells, hindering their ability to detect and destroy tumor cells, thus aiding immune evasion. Inhibitors that target the PD-1/PD-L1 pathway disrupt this interaction, thereby restoring the cytotoxic functions of T cells to efficiently attack and eliminate tumors, countering immune evasion [32]. Additionally, PD-L1 can be expressed by various cells within the tumor microenvironment (TME) [33, 34], creating an immunosuppressive milieu that further supports tumor progression [35, 36]. These cells not only suppress T cell activity via the PD-1/PD-L1 pathway but also secrete immunosuppressive cytokines, exacerbating immune evasion [37]. Additionally, conditions like hypoxia, elevated lactate levels, and nutrient deficiencies in the tumor microenvironment can lead to PD-L1 expression, thereby increasing the tumor’s ability to avoid immune detection [38]. In recent years, immunotherapies targeting the PD-1/PD-L1 axis have made substantial progress [39–41]. Inhibitors such as Nivolumab and Pembrolizumab for PD-1, as well as Atezolizumab and Durvalumab for PD-L1, have shown notable advancements, and have demonstrated notable efficacy across diverse cancer types. These drugs function by disrupting PD-1/PD-L1 interactions, releasing T cells from suppression, restoring their anti-tumor activity, and thereby achieving therapeutic efficacy.

Anti-PD-L1 and PD-1 therapies, widely used and recommended by European Society for Medical Oncology (ESMO) and the National Comprehensive Cancer Network (NCCN), are effective for urological cancers [42–47]. Atezolizumab and pembrolizumab, in particular, show significant results in advanced or metastatic bladder cancer, renal cell carcinoma, and prostate cancer. These therapies are suggested as first or second-line treatments, especially for patients who have failed chemotherapy or are ineligible for it, and have become essential in standard treatment regimens, greatly improving patient outcomes. This review seeks to establish a foundational understanding of the immune system’s structure and function, with a particular focus on the PD-1/PD-L1 axis. It summarizes key clinical trials that have resulted in the approval of the five PD-1/PD-L1 inhibitors currently used to treat urological cancers. Finally, the review addresses current and future challenges in the application of PD-1 and PD-L1 inhibitors, highlighting the essential role of predictive biomarkers.

PD-1/PD-L1 pathway: molecular and cellular mechanisms

Structure and function of PD-1 and PD-L1

PD-1 is a suppressive receptor found on the surface of immune cells such as T cells, B cells, and NK cells [48]. As a member of the immunoglobulin superfamily, PD-1 features an IgV-like extracellular domain, a transmembrane segment, and an intracellular region. The intracellular part includes an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM), both essential for PD-1 signaling [49]. Likewise, PD-L1, also part of the immunoglobulin superfamily, possesses an extracellular domain with IgV-like and IgC-like structures, a transmembrane component, and a cytoplasmic tail [50]. PD-L1 is broadly expressed in various cell types, including antigen-presenting cells (APCs), tumor cells, and certain non-immune cells [51]. The PD-1/PD-L1 pathway mainly dampens T cell activation and effector functions, ensuring immune system equilibrium [52]. The interaction between PD-1 and PD-L1 triggers downstream signaling pathways, particularly via the phosphatase SHP-2 containing Src homology 2 domain, which inhibits T cell receptor (TCR) and CD28 co-stimulatory signals [39, 53]. This results in suppressed T cell proliferation, cytokine production, and cytotoxic activity, potentially leading to T cell apoptosis or anergy [54, 55]. While this mechanism typically prevents autoimmune responses, tumor cells exploit it within the tumor microenvironment (TME) to escape immune detection.

Regulation of PD-1/PD-L1 expression

The expression of PD-1 and PD-L1 is influenced by a range of genetic and epigenetic elements. The promoter region of PD-1 has numerous sites for transcription factor binding, including nuclear factor kappa B (NF-κB), activator protein 1 (AP-1), and interferon regulatory factors (IRF), among others [56, 57]. These transcription factors can enhance PD-1 gene transcription under different stimulatory conditions. DNA methylation and histone modifications also critically influence PD-1/PD-L1 expression [58, 59]. High methylation of the PD-1 promoter is associated with low expression, whereas demethylation promotes its expression. Additionally, inhibition of histone deacetylases (HDACs) can increase PD-1 expression [60, 61]. The expression of PD-L1 is controlled by various signaling pathways, including those involving interferon-gamma (IFN-γ) and transforming growth factor-beta (TGF-β) [62, 63]. IFN-γ directly enhances PD-L1 transcription by activating IRF-1 [64]. Additionally, certain microRNAs (miRNAs) play a role in modulating PD-L1 levels [65]. Elements within the tumor microenvironment (TME) also trigger PD-L1 expression, aiding tumor cells in evading the immune response [66, 67]. Hypoxia significantly influences PD-L1 regulation through hypoxia-inducible factor 1-alpha (HIF-1α), which stabilizes and increases PD-L1 gene expression under low oxygen conditions [68]. Lactic acid, another key component of the TME, upregulates PD-L1 via the STAT3 signaling pathway [69]. Furthermore, cytokines such as IFN-γ, tumor necrosis factor-alpha (TNF-α), and interleukin-10 (IL-10) markedly boost PD-L1 expression levels [70, 71], typically secreted by immune cells infiltrating the tumor, such as T cells, macrophages, and dendritic cells (DCs) [72]. The model of PD-L1 and PD-1 interaction is displayed in Fig. 1.

Fig. 1 The model of PD-L1 and PD-1 interaction. T cell apoptosis is initiated when PD-L1 binds to its receptor PD-1, leading to T cell exhaustion and immune evasion. PD-1/PD-L1 antibodies disrupt the interaction between PD-1 and PD-L1, enabling T lymphocytes to reactivate, proliferate, and target tumor cells for destruction. PD-L1 expression is upregulated in response to inflammatory signals such as IFN-γ produced by activated T cells

PD-1/PD-L1 signaling in cancer and immune cells

PD-L1 is prominently upregulated in various cancer types, including urogenital cancers, where its high expression on tumor cells binds to PD-1 on T cells, effectively inhibiting T cell anti-tumor activity and promoting tumor growth and progression [73]. Furthermore, PD-L1 can be released via exosomes, further enhancing its inhibitory effects by engaging PD-1 [74]. This mechanism of immune evasion allows tumors to evade host immune surveillance and expand. PD-L1 is not confined to tumor cells but can also be expressed in stromal cells surrounding the tumor, which induce PD-L1 expression through the secretion of cytokines and growth factors [75]. Additionally, hypoxic conditions in the TME regulate PD-L1 expression through upregulation of HIF-1α, adding complexity to treatment strategies [76]. Beyond its role in tumor cells, the PD-1/PD-L1 signaling pathway plays a pivotal role in immune cell interactions [77]. In APCs like DCs and macrophages, PD-L1 expression regulates their functions, influencing antigen presentation and cytokine secretion [78]. PD-L1 inhibits DC maturation and function, thereby reducing their capacity to activate T cells and suppressing anti-tumor immune responses [79]. Additionally, the PD-1/PD-L1 pathway is critical in regulatory T cells (Tregs), enhancing their suppressive functions. PD-1 expression in Tregs helps maintain immune tolerance by secreting inhibitory cytokines and directly suppressing effector T cells (Teffs), thereby preventing excessive immune responses and autoimmune diseases [80]. In the TME, Tregs’ functions are exploited to support tumor immune evasion and growth. By augmenting Tregs’ activities, the PD-1/PD-L1 pathway further suppresses Teffs’ anti-tumor activity, fostering an immune-suppressive milieu that facilitates tumor survival and progression [81]. The potential mechanism of action of PD-1/PD-L1 in cells is shown in Fig. 2.

Fig. 2 The potential mechanism of action of PD-1/PD-L1 in cells. In the tumor immune microenvironment (TIME), various cells such as tumor (stromal) cells, certain antigen-presenting cells (APCs), regulatory T cells (Tregs), and M2 macrophages suppress the biological function of cytotoxic T lymphocytes (CTLs) through PD-1 signaling, leading to their exhaustion and apoptosis. Additionally, Tregs can downregulate the expression of CD80/CD86 costimulatory molecules on APCs and upregulate the expression of free PD-L1, exerting a dual inhibitory effect on CTLs. Furthermore, Tregs can secrete inhibitory cytokines and produce granzyme and perforin, causing damage to CTLs or APCs, thereby promoting tumor development. M2 macrophages also secrete growth factors and cytokines that contribute to tumor development and progression. Moreover, immunosuppressive cytokines are released to inhibit CTL metabolism and function

PD-1/PD-L1 in combination with other immune checkpoint inhibitors

The PD-1/PD-L1 pathway is one of several key immune checkpoints, along with molecules like cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), all essential in managing immune responses [82]. CTLA-4 functions by competitively binding to B7 molecules (CD80/CD86) during the initial T cell activation phase, thereby inhibiting CD28-mediated co-stimulatory signals and suppressing T cell activation [83]. Although the CTLA-4 and PD-1 pathways exhibit unique temporal and spatial characteristics, they can work together under certain conditions to amplify immune suppression. TIM-3, mainly found on exhausted T cells, inhibits T cell function by interacting with its ligand galectin-9 [54]. TIM-3 and PD-1 are commonly co-expressed in chronic infections and tumors, collectively dampening antigen-specific T-cell responses [84]. Lymphocyte activation gene-3 (LAG-3) is another crucial immune checkpoint molecule frequently co-expressed with PD-1 on exhausted T cells [85]. By binding to major histocompatibility complex (MHC) class II molecules, LAG-3 inhibits T-cell activation [53, 86]. The interactions of PD-1 with these immune checkpoints provide a rationale for combined immune therapies. For instance, combining PD-1 inhibitors with CTLA-4 inhibitors has demonstrated enhanced anti-tumor effects in certain cancers [87, 88]. This strategy works by simultaneously releasing constraints imposed by multiple inhibitory pathways, thereby bolstering T-cell responses against tumors.

The mechanisms of PD-1/PD-L1regulation in urological tumors

Regulation of PD-1/PD-L1 transcript levels in urologic malignancies

Transcription factors are essential protein molecules that bind specifically to upstream sequences at the 5’ end of genes, thereby regulating the expression of target genes with precise intensity at specific times and in particular spatial locations. Regulation at the transcriptional level plays a pivotal role in determining the level of gene expression. In models pertinent to urogenital tumors, numerous studies have elucidated mechanisms governing mRNA transcription, particularly focusing on PD-1/PD-L1 (especially PD-L1). These findings hold significant value for advancing our understanding of the role and underlying mechanisms of the PD-1/PD-L1 axis in the onset and progression of urogenital malignancies (Fig. 3; Table 1).

Fig. 3 Transcriptional regulation of PD-1/PD-L1 in urological malignancies. The key transcriptional mechanisms regulating the PD-1/PD-L1 axis in urological malignancies, including bladder, kidney, and prostate cancers. Highlighted are critical transcription factors (e.g., YY1, HIF-2α, STAT3, NF-κB) and their binding sites on the PD-L1 promoter, which enhance or suppress PD-L1 expression

Table 1 Transcriptional regulation of PD-1/PD-L1 in urological malignancies

Cancer	Target	Expression	Regulator	Bind site	Biological function	Reference	
PCa	PD-L1	Upregulation	YY1	Promoter	Reduce tumor-infiltrating CD4 + CD8 + T cells	[89]	
PD-L1	Upregulation	NF-κB	Promoter	Promote immune escape	[90]	
BCa	PD-L1	Upregulation	STAT3	Promoter	Promote immune escape	[92]	
PD-L1	Upregulation	c-Jun	Enhancer	Inhibit T cell function	[91]	
RCC	PD-L1	Upregulation	TFEB	Promoter	Reduce tumor-infiltrating CD8 + T cells	[93]	
PD-L1	Upregulation	TFE3	Promoter	Promote tumour cell proliferation and immune escape	[94]	
PD-L1	Upregulation	HIF2α	Promoter	Promote immune escape	[95]	

Several studies have examined the regulatory mechanisms influencing PD-L1 transcriptional levels in prostate cancer (PCa) models. For instance, Yin Yang 1 (YY1), a critical transcriptional regulatory factor, is crucial for tumor cell survival, proliferation, metabolism, epithelial-mesenchymal transition (EMT), and resistance to chemotherapy. YY1 directly interacts with the promoter region of the PD-L1 gene, boosting its transcription. Furthermore, YY1 indirectly influences PD-L1 expression through mechanisms involving p53, cytokines, growth factors, and the PTEN/PI3K/mTOR/AKT pathway. The upregulation of PD-L1 by YY1 significantly decreases the proportion of tumor-infiltrating CD4 + and CD8 + T cells [89]. Another key transcription factor in cancer is NF-κB, which is activated by pro-inflammatory cytokines like TNF-α through the MAP3K7-IKK signaling axis, regulating PD-L1 mRNA expression across various cancers. Huang et al.‘s CHIP-qPCR analysis discovered that the RelA/p65 protein within the NF-κB complex binds to the genomic sites of NF-κB target genes, including PD-L1. Furthermore, electrophoretic mobility shift assay (EMSA) confirmed the presence of a functional NF-κB binding site within the PD-L1 promoter. These findings indicate that NF-κB promotes PD-L1 transcription by directly binding to its promoter, thus facilitating immune evasion in tumors [90].

In BCa models, the transcriptional regulation of PD-L1 has also been extensively studied. c-Jun, part of the AP-1 transcription factor family, can be activated via the classic EGFR/MEK/ERK signaling pathway and binds to the enhancer region of the PD-L1 gene. This activation leads to increased PD-L1 expression and inhibits T-cell functions, identifying c-Jun as a key transcriptional regulator of PD-L1 expression [91]. Additionally, STAT3, a signal transducer and transcription activator, has been associated with the regulation of PD-L1 expression in BCa cells. Lu et al. investigated the interaction between SETD7 and STAT3, finding that STAT3 enhances immune evasion in BCa cells by increasing PD-L1 levels and facilitating tumor immune evasion. These insights suggest that STAT3 directly influences PD-L1 transcription by attaching to its promoter region. Nevertheless, further extensive research is required to confirm these hypotheses [92].

In RCC models, the transcriptional regulation of PD-L1 has been investigated as well. The transcription factor EB (TFEB), known for its role in lysosome biogenesis, autophagy, and metabolism regulation, has been linked to various human tumors. High expression of TFEB is associated with increased tumor cell proliferation and motility. Yang et al. discovered that TFEB directly attaches to the PD-L1 promoter region in RCC, thereby promoting PD-L1 transcription. This process inhibits the cytotoxic activity of tumor-infiltrating CD8 + T cells and enables immune evasion in RCC [93]. Similarly, the transcription factor E3 (TFE3), an essential oncogene in the proliferation of RCC cells, has been demonstrated to enhance PD-L1 expression by binding to its promoter. This regulatory pathway facilitates immune evasion and contributes to sunitinib resistance in RCC [94]. Moreover, hypoxia-inducible factor 2-alpha (HIF2-α), predominantly expressed in RCC cells, plays a significant role in promoting RCC progression. Kim et al. found that HIF2α attaches to hypoxia-response elements on the PD-L1 promoter, resulting in increased PD-L1 transcription. This mechanism also facilitates immune evasion in RCC [95].

Post-transcriptional modification of PD-1/PD-L1 in urologic malignancies

In the context of PD-1/PD-L1, negative regulation occurs through processes like ubiquitination, ubiquitin-like modifications, and methylation (Fig. 4; Table 2). Conversely, positive regulation involves deubiquitination, glycosylation, palmitoylation, ADP-ribosylation, and deacetylation [96]. Understanding these regulatory mechanisms and identifying new targets for modifying PD-1/PD-L1 are crucial for advancing precise immunotherapies for genitourinary malignancies.

Fig. 4 Posttranslational modifications of PD-1/PD-L1 in urological malignancies. The various posttranslational modifications (PTMs) of PD-1 and PD-L1 proteins in urological malignancies, including bladder, kidney, and prostate cancers. It highlights modifications such as deubiquitination, methylation, poly-ubiquitination and their specific sites on PD-1/PD-L1 molecules. The figure illustrates how these PTMs affect protein stability, localization, and interaction with other cellular components, ultimately influencing immune checkpoint function

Table 2 Posttranslational modifications of PD-1/PD-L1 in urological malignancies

Cancer	Target	Epigenetics modifications	Regulatory mechanism	Effects on PD-1/PD-L1	Biological function	Reference	
BCa	PD-L1	Deubiquitination	BCCE/USP18/ISG15	Enhance PD-L1 stability	Promote immune escape	[97]	
PD-L1	Methylation	JNK1/c-Jun/METTL3	Enhance PD-L1 stability and expression	Inhibit tumour cell apoptosis, promote immune escape	[98]	
PD-L1	Ubiquitination	FGFR3/NEDD4	Promote PD-L1 degradation	Promote cytotoxic activity of T cells	[99]	
PD-L1	Poly-ubiquitination	RNF144A	Promote PD-L1 degradation	Promote cytotoxic activity of T cells	[100]	
RCC	PD-1	Bind 3’UTR	TGFβ1/SRSF3	Enhance PD-1 stability and nuclear export	Suppress cytotoxic activity of T cells	[101]	
PD-L1	Deubiquitination	miR-224-5p/CCND1/cyclin D-CDK4/6/cullin 3-SPOP E3 ligase	Suppress PD-L1 degradation	Promote the resistance of tumour cells to T cell-dependent toxicity	[102]	

Wang et al. discovered a genetic variant (rs62483508) within the miRNA-responsive element of the long non-coding RNA BCCE4, which is significantly linked to a reduced risk of BCa in the Chinese population. Their research emphasized BCCE4’s role in upregulating USP18 expression by competitively inhibiting miR-328-3p. USP18, a member of the USP subfamily of deubiquitinases, increases PD-L1 protein stability by removing interferon-induced protein 15 (ISG15), which aids in immune escape in BCa cells [97]. Elevated METTL3 expression was also observed in BCa tissues. Further studies indicated that METTL3 expression is regulated through the JNK signaling pathway and the downstream transcription factor c-Jun. METTL3 enhances PD-L1 expression by affecting its methylation status, stabilizing PD-L1 mRNA, and reducing CD8 + T cell cytotoxicity against BCa cells, thereby promoting immune evasion [98]. Additionally, Fibroblast Growth Factor Receptor 3 (FGFR3) has been shown to influence PD-L1 ubiquitination, impacting the tumor microenvironment in BCa. FGFR3 phosphorylates the NEDD4 E3 ubiquitin ligase, facilitating K48-linked polyubiquitination of PD-L1, which leads to its degradation and enhances CD8 + T cell-mediated tumor cell death [99]. Lin et al. investigated the ubiquitination regulatory mechanisms of PD-L1 in BCa, focusing on the E3 ubiquitin ligase RNF144A, which is frequently mutated or epigenetically silenced in cancer and exerts tumor-suppressive effects. Their findings demonstrated that RNF144A interacts with PD-L1 on cell membranes and intracellular vesicles via its C-terminal region, promoting PD-L1 polyubiquitination and degradation. This mechanism enhances CD8 + T cell cytotoxic function and inhibits BCa progression [100].

Li et al. studied the mechanisms behind elevated PD-1 expression in T cells within RCC. They found that transforming growth factor beta 1 (TGFβ1) activates p38, leading to Ser10 phosphorylation of histone H3. This modification recruits RelA/p65, which increases the expression of SRSF3 and SRSF5 in T cells. SRSF3 directly binds to the 3’UTR of PD-1 mRNA through its RNA recognition motifs, enhancing PD-1 mRNA stability and nuclear export, thus increasing PD-1 expression on T cell surfaces. This process inhibits T cell cytotoxicity against RCC cells [101]. Another study by Li et al. highlighted the significant upregulation of miR-224-5p in extracellular vesicles (EVs) derived from RCC patient urine. They found that miR-224-5p suppresses cyclin D1 expression, leading to decreased activity of the cyclin D-CDK4/6 complex. This reduction inhibits the cullin 3-SPOP E3 ubiquitin ligase-mediated pathway responsible for PD-L1 ubiquitination and degradation, resulting in elevated PD-L1 expression levels in RCC cells. RCC cells can transfer these regulatory mechanisms of PD-L1 expression through EVs, enhancing resistance to T cell-mediated cytotoxicity [102].

Molecular mechanisms regulating the expression of PD-1/PD-L1 in urologic cancers

PD-1 and its ligand PD-L1 play a critical role in tumor therapy by effectively regulating anti-tumor immune responses [103]. PD-L1 is found in various tumors, while PD-1 is predominantly located on T cells within tumor tissues [104]. The interaction between PD-L1 and PD-1 forms a molecular barrier that suppresses immune cell cytotoxicity. By modulating the expression of PD-1/PD-L1, it is possible to reactivate immune responses and overcome this immune suppression [105]. Numerous studies have shown the therapeutic benefits of monoclonal antibodies that target PD-1 and PD-L1 in the treatment of urological cancers [106]. Therefore, understanding the regulatory mechanisms of PD-1/PD-L1 expression is essential for optimizing cancer immunotherapy in these malignancies (Fig. 5; Table 3).

Fig. 5 The molecular mechanism of regulating PD-1/PD-L1 in urological malignancies. The molecular pathways and mechanisms involved in the regulation of PD-1/PD-L1 expression in urological cancers, including signaling cascades, transcription factors, and posttranslational modifications that contribute to immune evasion and tumor progression

Table 3 The molecular mechanism of regulating PD-1/PD-L1 in urological malignancies

Cancer	Drug/Target	PD-1/PD-L1 expression
(inducer/inhibitor)	Mechanism	Biological function	Reference	
PCa	EZH2	PD-L1 inhibitor	Inhibit STING/PD-L1 axis or directely inhibit PD-L1	Increase tumor-infiltrating CD8 + T cells and M1 TAMs	[107]	
HnRNP L	PD-L1 inducer	YY1/PD-L1 axis	Inhibit cytotoxic activity of T cells	[89]	
NRP2	PD-L1 inducer	YAP/TAZ axis	Inhibit anti-tumor immune response	[109]	
pRB	PD-L1 inhibitor	Inhibit NF-κB/PD-L1 axis	Enhance tumor immune response	[90]	
CFF-1	PD-L1 inhibitor	Inhibit EGFR/JAK1/STAT3 axis	Inhibit tumour cell proliferation, promote tumour cell apoptosis; lower PSA, better OS	[108]	
BCa	TGF-β	PD-L1 inducer	Promote the nuclear translocation of the PKM2 dimer and p-STAT3 complex; activate Smad-JAK2-STAT3 signaling pathway	Reduce tumor-infiltrating CD8 + T cells; promote tumour growth	[110]	
AR	PD-L1 inducer	ADAR2/circ_0001005/miR-200a-3p axis	Promote immune escape; lower PFS	[122]	
NAMPT	PD-L1 inhibitor	Regulate the IFN-γ-induced signaling pathways	Promote tumour cell proliferation, migration; reduce tumor-infiltrating CD8 + T cells	[123]	
MTHFD2	PD-L1 inducer	MTHFD2/PI3K/AKT/PD-L1 axis	Promote tumour cell proliferation and immune escape	[120]	
MTHFD2	PD-L1 inducer	MTHFD2/JAK/STAT/PD-L1 axis	Promote tumour cell proliferation, migration, and invasion, inhibit tumour cell apoptosis; promote tumour growth and immune escape	[113]	
RCC	RRM2	PD-L1 inducer	ANXA1/AKT/NF-κB axis	Promote tumour cell proliferation, tumour growth and immune escape	[124]	
FBW7	PD-L1 inducer	FBW7/NFAT1 axis	Increase tumor-infiltrating CD4 + CD8 + T cells	[111]	
EGFR	PD-L1 inducer	EGFR/ERK/c-Jun axis	Promote immune escape	[116]	
TFE3	PD-L1 inducer	TFE3/PI3K/AKT/mTOR axis	Promote immune escape	[121]	
TOPK	PD-L1 inducer	Activate ERK2 pathway; regulate TGF-β/Smad axis	Promote tumour cell proliferation, migration; reduce tumor-infiltrating CD8 + T cells	[22]	
IFN-γ	PD-L1 inducer	Activate IFN-γ/JAK/STAT1/IRF1 axis	/	[122]	
Glutamine	PD-L1 inhibitor	Inhibit EGFR/ERK/c-Jun axis	Inhibit immune escape	[119]	
IFN-γ	PD-L1 inducer	Regulate JAK2/STAT1/IRF-1 axis	Promote immune escape	[95]	
GHITM	PD-L1 inhibitor	GHITM/Notch1/PD-L1 axis	Inhibit tumour cell proliferation, migration, and invasion; inhibit lung metastasis	[125]	

Suppressing the epigenetic regulator EZH2 activates the double-stranded RNA-STING-interferon signaling pathway, resulting in the upregulation of genes related to antigen presentation, Th1 chemokine signals, and interferon responses, including PD-L1. Studies have shown that inhibiting EZH2 directly increases PD-L1 mRNA levels in PCa cell lines and human PCa tissues, thereby enhancing PD-L1 expression and improving the responsiveness of PCa to PD-1 checkpoint inhibitors [107]. In metastatic castration-resistant PCa, researchers found that phosphorylated retinoblastoma protein (pRB) suppresses NF-κB activity by interacting with its RelA/p65 subunit, reducing PD-L1 expression and promoting anti-tumor immune responses. Traditional Chinese medicine CFF-1 has also been reported to inhibit PD-L1 expression in PCa by suppressing the EGFR/JAK1/STAT3 axis, thus impeding cancer progression [108]. Additionally, Mao et al. demonstrated that heterogeneous nuclear ribonucleoprotein L (HnRNP L) enhances YY1 stability by binding to YY1 mRNA, leading to increased YY1 expression. YY1, a transcriptional regulator, binds to the PD-L1 gene promoter, promoting PD-L1 transcription and inhibiting T-cell cytotoxicity [89]. Another study indicated that Neuropeptide-2 activates Rac1, promoting YAP/TAZ nuclear translocation and transcriptional activity, consequently upregulating PD-L1 expression and suppressing anti-tumor immune responses [109].

The JAK (Janus kinase) signaling pathway is essential for various physiological processes and disease development. This pathway includes JAK1, JAK2, JAK3, and TYK2 kinases, which relay external signals from cell membrane receptors like cytokine and immunoglobulin receptors. When these receptors are activated, JAK proteins get phosphorylated and activated, initiating downstream signaling. Activated JAK proteins then phosphorylate and activate STAT proteins, which move to the nucleus to regulate gene transcription, affecting cell proliferation, differentiation, and apoptosis. Thus, the JAK pathway is crucial for immune regulation, cell growth, and cancer development. Abnormal activation of this pathway is linked to inflammatory diseases, autoimmune disorders, and various cancers. Therefore, understanding and controlling the JAK pathway is vital for treating and preventing these conditions. In BCa, tumor-associated macrophages (TAMs), especially M2-type TAMs, are crucial in promoting immune evasion and tumor progression. M2-type TAMs secrete TGF-β, which induces STAT3 phosphorylation and nuclear translocation, and promotes pyruvate kinase M2 (PKM2) dimerization, collectively enhancing PD-L1 expression. TGF-β also triggers the canonical Smad signaling pathway, which activates the JAK2/STAT3 signaling cascade, directly regulating PD-L1 expression and driving BCa progression [110]. Expression of FBW7, an F-box protein within the Skp1-Cul1-F-box protein ubiquitin ligase complex, is reduced in drug-resistant RCC models and patient samples, and its protein levels inversely associated with nuclear factor of activated T cells 1 (NFAT1) in RCC patients. FBW7 directly interacts with NFAT1 and regulates PD-L1 expression by modulating the JAK-STAT, TNF, and HIF pathways [111]. PD-L1 expression is differentially regulated in clear cell RCC and papillary RCC, with PD-L1 expression in clear cell RCC being dependent on intact IFN-γ signaling, activating JAK2/STAT1/IRF1 to promote PD-L1 transcription. Conversely, PD-L1 expression in papillary RCC is independent of IFN-γ signaling, highlighting distinct mechanisms in different RCC subtypes [95, 112]. Heng et al. also linked elevated MTHFD2 expression in BCa cells and tissues with adverse clinical outcomes, showing that MTHFD2 promotes PD-L1 expression by activating the JAK/STAT signaling pathway, highlighting its role in immune regulation within the BCa microenvironment [113].

The ERK (extracellular signal-regulated kinase) signaling pathway is a vital intracellular mechanism essential for cell proliferation, differentiation, survival, and migration. It is part of the RAS-RAF-MEK-ERK cascade, also known as the MAPK (mitogen-activated protein kinase) pathway. This pathway detects external signals via cell surface receptors, such as growth factor and cytokine receptors. Signal transduction starts with receptor activation, leading to RAS protein activation, which then activates RAF kinase. RAF kinase phosphorylates and activates MEK, which subsequently activates ERK. Activated ERK moves into the nucleus to phosphorylate target proteins, including transcription factors, thus regulating gene expression and cell functions. Dysregulation of the ERK pathway is linked to various diseases, particularly cancer, where it promotes uncontrolled cell proliferation and resistance to apoptosis. The ERK pathway also plays roles in cardiovascular, neurological, and immune diseases. Understanding its regulatory mechanisms is crucial for uncovering the molecular basis of these diseases and developing new treatments. The TME is marked by hypoxia and acidity from glycolysis-induced lactate buildup, facilitating tumor cell migration and invasion [114, 115]. Niu et al. found that glucose metabolism influences PD-L1 expression in RCC via the EGFR/ERK/c-Jun pathway. Elevated PD-L1 expression also upregulates PFKFB3 to regulate glycolysis, suggesting potential combined therapeutic targets in RCC [116]. T-LAK cell-originated Protein Kinase (TOPK) regulates PD-L1 expression to promote immune evasion in RCC through two mechanisms. TOPK forms a positive feedback loop with ERK2 and enhances the TGF-β/Smad pathway by directly binding to Smad4, thereby promoting PD-L1 expression [117]. Glutamine is a versatile nutrient crucial for various metabolic pathways within tumor cells. In the TME, glutamine levels are notably low, often reaching undetectable levels compared to normal tissues [118]. Studies highlight that reduced glutamine metabolism in RCC cells correlates with high PD-L1 expression levels. Mechanistically, glutamine deprivation activates the Epidermal Growth Factor Receptor (EGFR), ERK1/2, and c-Jun, resulting in high PD-L1 expression. In turn, high PD-L1 levels contribute to T-cell suppression and facilitate immune evasion of RCC [119].

The PI3K/AKT pathway is an essential intracellular signaling route that regulates cell growth, proliferation, metabolism, and survival. This pathway involves PI3K and AKT, which respond to signals from various receptors like growth factor, insulin, and cytokine receptors. Activation of these receptors leads to PI3K activation at the cell membrane, converting PIP2 to PIP3. PIP3 then activates AKT, which phosphorylates targets like mTOR, GSK-3β, and BAD, controlling cell functions. Abnormal PI3K/AKT activation is linked to diseases such as cancer, where it promotes rapid growth, apoptosis resistance, increased metabolism, and invasiveness. It also plays roles in diabetes, cardiovascular, and neurodegenerative diseases. Understanding this pathway is essential for disease research and developing new treatments. Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) has been implicated in various malignancies, including BCa. Higher MTHFD2 expression in BCa tissues is associated with poor prognosis, increased tumor immune cell infiltration, and elevated PD-L1 levels. Transcriptome analysis reveals that MTHFD2 expression correlates positively with the activation of the PI3K/AKT signaling pathway, which enhances PD-L1 expression [120]. TFE3, involved in autophagy and lysosome biogenesis, shows elevated expression and activity in various human cancers, including RCC. TFE3 upregulates PD-L1 expression by activating the PI3K/AKT/mTOR pathway, and mTOR inhibitors may further enhance PD-L1 expression by increasing TFE3 activity [121].

In addition, other pathways also play important roles in regulating PD1/PD-L1. The androgen receptor (AR) positively influences PD-L1 expression; miR-200a-3p targets the 3’UTR region of PD-L1 mRNA to suppress its expression. AR upregulates circ_0001005 by modulating the ADAR2 enzyme, and circ_0001005 acts as a competitive inhibitor of miR-200a-3p, thereby reducing miR-200a-3p levels and increasing PD-L1 expression, diminishing NK cell cytotoxicity and promoting immune evasion in BCa [122]. Finally, Nicotinamide phosphoribosyltransferase (NAMPT) has been identified as a negative regulator of PD-L1 expression in BCa. Upregulated NAMPT levels in BCa patients inversely correlate with immune cell infiltration, and it has been shown that NAMPT downregulates PD-L1 expression via an IFN-γ-dependent mechanism, suggesting NAMPT as a potential target for immune checkpoint regulation [123]. Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) is crucial for deoxyribonucleotide synthesis following ribonucleotide reduction and is considered a proto-oncogene due to elevated expression in various cancers. Jin et al. demonstrated that RRM2 upregulates ANXA1 levels, activation, and subsequent PD-L1 expression enhancement, which augments the anti-tumor efficacy of PD-1 blockade therapy [124]. Growth hormone-inducible transmembrane protein (GHITM), a member of the the Bax inhibitor-1 family, is downregulated in RCC and correlates with adverse patient prognosis. Furthermore, Wang et al. demonstrated that GHITM indirectly inhibits PD-L1 expression by suppressing the oncogene Notch1 thereby reducing RCC tumor progression and lung metastasis, suggesting its potential as a therapeutic target [125].

Anti-PD-1 /PD-L1 combination therapy in urinary malignancies

Because of the inherent variability of cancer and the genetic diversity among individuals, single-agent therapies that target the PD-1/PD-L1 pathway have failed to yield satisfactory results [126]. As a result, there is a pressing need for personalized combination therapies designed for individual patients to enhance response rates to PD-1/PD-L1 inhibitors and to overcome resistance to anti-PD-1/PD-L1 treatments. Recent research highlights that integrating anti-PD-1/PD-L1 therapy with other immune checkpoint inhibitors (ICIs) targeted therapies against VEGF/VEGFR, tumor vaccines, oncolytic viruses (OVs), and approaches that can increase the efficacy of PD-1/PD-L1 blockade [127, 128]. Significantly, these strategies have demonstrated initial success in the treatment of genitourinary malignancies (Fig. 6; Table 4).

Fig. 6 Combined therapy with anti-PD-1/PD-L1 in the treatment of urological malignancies. Co-administration of anti-PD-1/PD-L1 therapies in urological malignancies demonstrates enhanced antitumor efficacy

Table 4 Combined therapy with anti-PD-1/PD-L1 in the treatment of urological malignancies

Cancers	anti-PD-1/PD-L1	Combined drug	Biological function	Outcome	Reference	
PCa	anti-PD-1	anti-LAG-3	Increase tumor-infiltrating CD8 + memory T cells	Suppress tumor growth	[129]	
	anti-PD-1	Nitroxoline	Increase memory T cells and MDSC by inhibiting the PI3K/AKT/mTOR signaling pathway	Suppress tumor growth, lower PSA	[133]	
	anti-PD-1	rAd-p53	Increase tumor-infiltrating CD4 + CD8 + T cells	Suppress tumor growth, better OS	[134]	
	anti-PD-1	Docetaxel	Restore T cell function; inhibit PI3K/AKT/NF-κB-P65/PD-L1 axis	better OS	[135]	
	anti-PD-1	Anti-Tim-3	Reduce immune suppressive factors and enhance CD8 + T cell function	Suppress tumor growth	[130]	
	anti-PD-1	Ibrutinib	Inhibit immunosuppressive B cells and increase CD8 + T cells	Suppress tumor growth, better OS	[136]	
BCa	anti-PD-1	anti-TNF-α/CD47/Ly6G	/	Suppress tumor growth, overcome resistance, tumor shrinkage	[139]	
	anti-PD-L1	anti-TIGIT	Increase the CD8 + TILs released cytokines	/	[137]	
	anti-PD-1	OXP	Increase infiltration and regulate the phenotype of immune cells in TME	/	[140]	
	anti-PD-1	S100A5 knockdown	Suppress the infiltration and function of CD8 + T cells	Suppress tumor growth	[141]	
	anti-PD-1	anti-CTLA-1	Promote Th1-type immune response and activate of the IFN-γ signaling pathway in endothelial cells	Suppress tumor growth	[138]	
	anti-PD-1	anti-FGFR	Inhibit Treg expansion	/	[142]	
	anti-PD-L1	VAX014	Increase the proportion of Th1 cells and activated CD8 + T cells in TILs	better OS	[143]	
RCC	anti-PD-1	αKG	Increase tumor-infiltrating CD8 + T cells by αKG-B2M-CD8 axis	Suppress tumor growth, better OS	[144]	
	anti-PD-1	lenvatinib	Inhibit the FGFR signaling pathway; modulate TME	Suppress tumor growth, better OS	[145]	
	anti-PD-1	anti-LAG-3	Promote proliferation, degranulation, and cytokine secretion of TILs	/	[147]	
	anti-PD-1	sunitinib	/	Suppress lung metastasis, better OS	[146]	
	anti-PD-1	JX-594	Remodel the tumor immune microenvironment; reduce immune-related toxicity	Suppress tumor growth and lung metastasis	[3]	
	anti-PD-1	Acarbose	Increase tumor-infiltrating CD8 + T cells	Suppress tumor growth and lung metastasis	[148]	

LAG-3 is an immune checkpoint inhibitor primarily found on activated T-cells, which curtails T-cell function and proliferation, thereby reducing anti-tumor immune responses. In mouse models of prostate cancer, simultaneous blocking of PD-1 and LAG-3 results in increased infiltration of CD4 + and CD8 + T cells into tumors. Specifically, CD8 + T cells predominantly exhibit effector memory and tissue-resident memory traits. This combination therapy markedly suppresses tumor growth compared to the use of PD-1 or LAG-3 inhibitors alone [129]. Tim-3, co-expressed with PD-1 in TME, represents a marker of T-cell exhaustion and research shows that blocking PD-1 increases Tim-3 levels. Using inhibitors targeting both PD-1 and Tim-3 enhances anti-tumor immunity by improving CD8 + T cell activity, diminishing tumor-supportive factors, and further reducing tumor growth [130]. Nitroxoline, commonly utilized for urinary tract infection treatment, has shown promise as an anticancer agent effective against multiple cancer forms [131, 132]. Huang et al.‘s research demonstrate that Nitroxoline, when combined with PD-1 blockade, shows significant potential in treating PCa. Nitroxoline inhibits the PI3K/AKT/mTOR pathway to reduce PD-L1 expression, thereby boosting the immune response of PD-1 blockade. This therapeutic approach increases memory T cells and decreases myeloid-derived suppressor cells, presenting a promising treatment option [133]. Gene therapy can be used to stimulate immune responses within the TME by directly injecting virus vectors carrying specific genes into tumor sites. For example, the replication-deficient recombinant adenovirus vector rAd-p53, which carries the human p53 gene, boosts the infiltration of CD4 + and CD8 + T cells into tumors and increases PD-L1 expression on tumor cells, thus improving the effectiveness of anti-PD-1 antibody therapy [134]. Docetaxel, an FDA-approved taxane used for prostate cancer (PCa) chemotherapy, has been studied in conjunction with PD-1 inhibitors in PCa mouse models. This combined therapy mitigates the docetaxel-induced increase in PD-L1 expression, reversing tumor immune evasion. Furthermore, it enhances the infiltration of CD4 + and CD8 + T cells into tumors, restores immune functionality, and inhibits the PI3K/AKT/NF-κB-P65/PD-L1 signaling pathway. Consequently, it overcomes chemotherapy resistance induced by docetaxel and promotes apoptosis in tumor cells [135]. Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) anchored vaccine represents a novel immunotherapy method. By fixing GM-CSF protein on tumor cell surfaces using a biotin-avidin system, this approach stimulates bone marrow cell proliferation and enhances anti-tumor immune responses. Infiltrating B lymphocytes within the PCa TME exhibit immunosuppressive properties that promote tumor growth. Bruton’s tyrosine kinase (BTK), a critical regulator of B cell function, is targeted by the inhibitor ibrutinib, which demonstrates anti-tumor effects in PCa. While monotherapy with ibrutinib reduces B cell infiltration and activation in the TME without shrinking tumors, combined therapy of ibrutinib and anti-PD-1 ICIs significantly enhances anti-tumor immune responses and reduces tumor volume in preclinical models [136].

T-cell immunoglobulin and ITIM domain (TIGIT) is a negative immune checkpoint receptor found on activated T cells. Its interaction with the ligand CD155 leads to diminished anti-tumor activity of CD8 + T cells by inducing exhaustion. Studies show that blocking TIGIT boosts cytokine production by CD8 + tumor-infiltrating lymphocytes (TILs) and works in tandem with PD-1 blockade in breast cancer (BCa) patients. This indicates that TIGIT and PD-1 jointly inhibit CD8 + T cell effector function, supporting the combined blockade to revive anti-tumor responses [137]. CTLA-4, another inhibitory immune checkpoint receptor present on activated T cells, suppresses their activation and proliferation. Within the BCa TME, CTLA-4 aids in immune evasion. Simultaneously blocking PD-1 and CTLA-4 in mouse BCa models significantly curtails tumor growth by enhancing Th1-type immune responses and triggering IFN-γ signaling pathways in endothelial cells [138]. To combat resistance to PD-1/PD-L1 therapy in bladder cancer, Dumontet and colleagues created a resistant mouse model and investigated combination therapy targets. They found that targeting TNF-α, CD47, and Ly6G in conjunction with anti-PD-1 treatment significantly inhibited tumor growth and overcame resistance more effectively than anti-PD-1 monotherapy [139]. Oxaliplatin (OXP), a second-line chemotherapy for bladder cancer (BCa), when paired with anti-PD-1 inhibitors, demonstrates superior efficacy in reducing tumor growth compared to either treatment used individually. This therapy combination improves immune cell infiltration into the tumor microenvironment (TME) and adjusts immune cell phenotypes to strengthen anti-tumor immune responses [140]. S100A5, a tumor-specific protein, inhibits CD8 + T cell proliferation and cytotoxicity, thereby promoting tumor survival. Indeed, knocking down S100A5 or using anti-PD-1 monotherapy boosts CD8 + T cell infiltration and cytotoxicity, significantly hindering tumor growth and a combination of S100A5 knockdown along with anti-PD-1 therapy demonstrates superior anti-tumor efficacy [141]. Fibroblast Growth Factor Receptor (FGFR) mutations activate Tregs in the TME, impeding anti-PD-1 therapy efficacy. Erdafitinib, an FGFR inhibitor, reverses this immunosuppressive effect. Combining Erdafitinib with PD-1 inhibitors enhances CD8 + T cell infiltration, augments anti-tumor immune response, and therapeutic outcomes [142]. VAX014, an engineered bacterial minicell-based oncolytic agent, selectively targets and kills α3β1 and α5β1 integrin-expressing tumor cells, inducing anti-tumor immune responses. Intravesical VAX014 combined with systemic PD-L1 blockade enhances systemic anti-tumor immunity, prolonging survival by increasing Th1 cells and activating CD8 + T cells among TILs [143].

αKG (alpha-ketoglutarate) serves as a critical intermediate in the tricarboxylic acid (TCA) cycle. In RCC tissues, αKG levels are markedly reduced compared to normal tissues and inversely correlate with tumor malignancy. This suggests a protective role for αKG in inhibiting tumor initiation and progression. Research by Wang et al. further demonstrated that αKG alone or in combination with anti-PD-1 antibodies can inhibit tumor growth, as expected combination therapy was shown to be more effective than monotherapy. By modulating the αKG-B2M-CD8 axis, combination therapy enhances the infiltration of CD8 + T cells into the TME and extends overall survival in murine models [144]. Renetinib, a multi-target tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR-α, RET, and KIT, has been approved for advanced RCC treatment. Studies show that Renetinib enhances tumor cell sensitivity to IFN-γ signaling by inhibiting the FGFR pathway. Preclinical models demonstrate that using a combination of Renetinib and anti-PD-1 antibodies significantly decreases tumor size and extends survival more effectively than anti-PD-1 monotherapy [145]. Sunitinib, a small molecule inhibitor targeting VEGFRs, demonstrates efficacy in RCC by prolonging survival and inhibiting metastasis. However, its efficacy alone may be limited. Research indicates that combining Sunitinib with anti-PD-L1 therapy is more effective than either treatment alone, significantly extending survival and suppressing lung metastasis [146]. PD-1 blockade leads to increased LAG-3 expression on CD4 + and CD8 + T cells. Combined PD-1 and LAG-3 blockade enhances IFN-γ secretion by CD8 + T cells and improves the overall functionality of TILs compared to PD-1 blockade alone [147]. JX-594, a genetically modified oncolytic virus expressing GM-CSF, activates dendritic cells and induces anti-tumor effects through oncolysis and immune stimulation. Combination therapy with JX-594 and PD-1 inhibitors in metastatic RCC reshapes the tumor immune microenvironment, enhances anti-tumor immune responses, and reduces immune-related toxicity, demonstrating efficacy and safety in preclinical models. Acarbose, an inhibitor of oligosaccharide hydrolysis, modulates glucose metabolism in the TME, enhancing CD8 + T cell anti-tumor immune function. Combination therapy with acarbose and anti-PD-1 significantly enhances the cytotoxic function of CD8 + T cells infiltrating tumors, inhibits RCC tumor growth, and reduces lung metastases compared to anti-PD-1 monotherapy [148].

The clinical trial of PD-1/PD-L1 inhibitors in urological tumors

In the domain of urological cancers such as BCa, RCC, and PCa, PD-1/PD-L1 inhibitors have become essential treatment options. BCa, in particular, has gained significant attention, as illustrated by the IMvigor210 trial, which assessed the efficacy of the PD-L1 inhibitor Atezolizumab in patients with advanced urothelial carcinoma after chemotherapy. The trial revealed notable anti-tumor effects, achieving an objective response rate (ORR) of 15% [149, 150]. Similarly, KEYNOTE-045 investigated Pembrolizumab, a PD-1 inhibitor, showing improved overall survival compared to chemotherapy in advanced BCa [151, 152]. Promising results have been observed with PD-1/PD-L1 inhibitors in advanced RCC treatment. The CheckMate 025 trial assessed Nivolumab in patients with advanced RCC, revealing better overall survival and higher ORRs compared to Everolimus [153, 154]. Moreover, the CheckMate 214 study investigated the combination of Nivolumab and the CTLA-4 inhibitor Ipilimumab, yielding notable outcomes in patients with intermediate and poor risk [155]. PCa exhibits limited response to PD-1/PD-L1 inhibitors overall, though promising efficacy has been observed in specific subgroups. The KEYNOTE-199 trial in metastatic castration-resistant PCa revealed modest overall ORRs in patients treated with Pembrolizumab but efficacy in subgroups carrying DNA repair gene mutations [156]. Future research directions include optimizing PD-1/PD-L1 inhibitor applications through combination therapies, identifying patient subgroups most likely to benefit, and expanding exploration into their potential across urological cancers. While significant strides have been made, further investigations are crucial to fully harnessing their therapeutic potential in clinical practice. The ongoing clinical trials exploring the efficacy of anti-PD-1 and anti-PD-L1 in urological malignancies are shown in Tables 5 and 6.

Table 5 The ongoing clinical trials exploring the efcacy of anti-PD-1 in urological malignancies

Cancer type	Clinical trial	Anti-PD-1	Phase	Primary outcome measures	
PCa	NCT03637543	Nivolumab	2	Disease Control	
	NCT03093428	Pembrolizumab	2	Number of Participants With Increased Immune Cell Infiltration Across Arms	
	NCT05733351	Vudalimab	1	Incidence of Adverse Events	
				Radiographic Progression-Free Survival	
	NCT05848011	Lorigerlimab	2	Median radiographic progression free survival (rPFS)	
	NCT03506997	Pembrolizumab	2	To evaluate tumour response	
	NCT03910660	Pembrolizumab	1 + 2	Phase 2a: Estimate the composite response rate of the combination of BXCL701 + PEMBRO	
				Phase 2b: Evaluate response rates in patients treated with the combination of BXCL701 + PEMBRO and with BXCL701 monotherapy	
BCa	NCT05564897	Camrelizumab	2	complete response (CR)	
	NCT05975307	Toripalimab	2	Clinical complete response (cCR) rate	
	NCT05401279	Tislelizumab	2	Two-year bladder-intact disease-free survival rate	
	NCT05072600	Pembrolizumab	2	PFS	
	NCT05241340	Sasanlimab	2	Composite outcome for Feasibility and Safety	
				Clinical benefit rate defined as pathologic complete response (pT0)	
	NCT04134000	Atezolizumab	1	Dose limiting toxicity (DLT)	
				Recurrence free survival	
	NCT03179943	Atezolizumab	2	Maximum tolerated dose of Guadecitabine in combination of Atezolizumab in safety run-in phase	
				Objective Response Rate (RECIST v 1.1) in Phase II	
RCC	NCT04006522	Atezolizumab	2	Correlation between 89Zr-DFO-Atezolizumab and PD-L1	
				Correlation between 89Zr-DFO-Atezolizumab and anti-PD1/PD-L1 therapy	
	NCT05148546	Nivolumab	2	Pathologic response rate	
	NCT03172754	Nivolumab	1 + 2	Incidence of treatment-related adverse events	
				Overall response rate (ORR)	
	NCT05215470	Nivolumab	2	Overall Survival	
				Progression-free survival	
	NCT05935748	Sasanlimab	2	Number of Participants with Dose Limiting Toxicity (DLT) events during the DLT monitoring period (first 28 days of dosing) in the Lead-in Phase	
				Objective Response Rate (ORR) determined by the Investigator	
	NCT06364631	Nivolumab	3	Overall Survival (OS)	
	NCT05877820	Tislelizumab	2	Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)	
	NCT03260894	Pembrolizumab	3	Objective Response Rate (ORR) of Pembrolizumab + Epacadostat Versus Standard of Care (SOC)	
	NCT05969496	Pembrolizumab	2	Evaluate Change in IVC Tumor Thrombus Extent Based on the Mayo Classification	
				Evaluate a change in IVC TT Size from Baseline	
	NCT04370509	Pembrolizumab	2	Proportion of participants with > = 2-fold increase in the number of tumor-infiltrating immune cells (TIICs)	

Table 6 The ongoing clinical trials exploring the efcacy of anti-PD-L1 in urological malignancies

Cancer type	Clinical trial	Anti-PD-L1	Phase	Primary outcome measures	
PCa	NCT03795207	Durvalumab	2	Two-years Progression-free survival	
	NCT04751929	Atezolizumab		6-month Progression free survival (PFS) rate	
				Objective response rate (ORR)	
				Rate of Dose Limiting Toxicity (DLT)	
				Rate of Adverse Events	
	NCT04009967	Pembrolizumab	2	The antitumor activity of pembrolizumab assessed as the tumor response rate based on the change in tumor volume as measured by 18FDG-PET	
				Mean difference change in proliferative index in prostate cancer patients between patients treated with pembrolizumab and the control cohort	
				Immune cell infiltration and immune checkpoint expression	
	NCT02998567	Pembrolizumab	1	Establish maximum tolerated dose (MTD)	
				Measure Adverse Events according to CTCAE v4.0	
	NCT02312557	Pembrolizumab	2	PSA response, defined by a PSA decrease of at least 50% confirmed by a second measurement at least 3 weeks later	
	NCT04191096	Pembrolizumab	3	Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)	
				Overall Survival (OS)	
	NCT02861573	Pembrolizumab	1 + 2	Percentage of Participants With a Decrease of ≥ 50% in Prostatic Specific Antigen (PSA)	
				Number of Participants with Adverse Events (AEs)	
				Number of Participants Discontinuing Study Drug Due to AEs	
				Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR)	
	NCT05568550	Pembrolizumab	2	Clinical Response Rate	
	NCT03506997	Pembrolizumab	2	To evaluate tumour response	
BCa	NCT05843448	Pembrolizumab	1	Incidence of adverse events	
	NCT03697850	Atezolizumab	2	Disease Free Survival	
	NCT04106115	DURvalumab	1 + 2	Occurrence of Dose Limiting Toxicity (Phase 1b)	
				Pathological Disease Free Survival Rate (DFSR) (Phase 2)	
	NCT03732677	Durvalumab	3	Pathologic complete response (pCR) rates at time of cystectomy	
				Event-free survival (EFS) per central review defined as time from randomization to event	
	NCT03601455	Durvalumab	2	Incidence of adverse events assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4.03 criteria (Safety lead-in cohort)	
				Progression- free survival (PFS) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 (Expansion cohort)	
	NCT04138628	Atezolizumab	2	Complete response (CR) after treatment with investigational agent initiated by ctDNA positive status after radical cystectomy (with or without concomitant visible metastases on CT).	
	NCT04134000	Atezolizumab	1	Dose limiting toxicity (DLT)	
				Recurrence free survival	
	NCT06305767	Pembrolizumab	2	Disease Free Survival (DFS)	
	NCT03924895	Pembrolizumab	3	Event-Free Survival (EFS) between Arm C and Arm B	
	NCT02625961	Pembrolizumab	2	Cohort A: Complete Response (CR) Rate of High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)	
				Cohort B: 12-month Disease-Free Survival (DFS) Rate of High-Risk NMIBC	
				Cohort C: 12-month CR Rate of High-Risk NMIBC	
				All Cohorts: Number of Participants Who Experience an Adverse Event (AE)	
				All Cohorts: Number of Participants Who Discontinue Study Treatment Due to an AE	
	NCT05406713	Pembrolizumab	2	Clinical Complete Response Rate (CRR)	
				Benefit from Treatment	
	NCT03924856	Pembrolizumab	3	Event-Free Survival (EFS)	
	NCT03711032	Pembrolizumab	3	Complete Response Rate (CRR) by Blinded Independent Central Review (BICR) (Cohort A)	
				Event-Free Survival (EFS) (Cohort B)	
	NCT03513952	Atezolizumab	2	Objective response rate (ORR)	
	NCT04660344	Atezolizumab	3	Investigator-assessed DFS	
	NCT02812420	Durvalumab	1	Incidence of adverse events determined by extreme toxicity	
	NCT03528694	Durvalumab	3	The efficacy of Durvalumab + BCG (induction plus maintenance) combination therapy compared to SoC in terms of Disease free survival (DFS) in patients with NMIBC	
	NCT03244384	Tislelizumab	3	Overall survival	
				Disease-free survival	
	NCT03179943	Atezolizumab	2	Maximum tolerated dose of Guadecitabine in combination of Atezolizumab in safety run-in phase	
				Objective Response Rate (RECIST v 1.1) in Phase II	
RCC	NCT04006522	Atezolizumab	2	Correlation between 89Zr-DFO-Atezolizumab and PD-L1	
				Correlation between 89Zr-DFO-Atezolizumab and anti-PD1/PD-L1 therapy	
	NCT02853331	Pembrolizumab	3	Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Imaging Review	
				Overall Survival (OS)	
	NCT04955743	Pembrolizumab	2	Best brain metastasis response rate (BMRR)	
	NCT03142334	Pembrolizumab	3	Disease-free Survival (DFS) as Assessed by the Investigator	
	NCT05899049	Pembrolizumab	3	Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)	
				Overall Survival (OS)	
	NCT04698213	Avelumab	2	Overall response rate (ORR)	
	NCT05024318	Pembrolizumab	2	mPR post-SABR with or without pembrolizumab	
				CD8 + TRM in baseline biopsy and post-nephrectomy specimen, all measured as a continuous variable.	
				TCF-1 + tumour infiltrating lymphocytes (TILs) in baseline biopsy and post-nephrectomy specimen, measured as a continuous variable	
	NCT04704219	Pembrolizumab	2	Objective Response Rate (ORR)	
	NCT02684006	Avelumab	3	Progression Free Survival (PFS) in PD-L1 positive patients	
				Overall Survival in PD-L1 positive patients	
	NCT06307431	Pembrolizumab	2	Disease-Free Survival (DFS)	
	NCT04736706	Pembrolizumab	3	Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)	
				Overall Survival (OS)	
	NCT05567588	Pembrolizumab	2	ORR	
	NCT05239728	Pembrolizumab	3	Disease-Free Survival (DFS)	
	NCT03308396	Durvalumab	1 + 2	Phase Ib: Dose limiting toxicities will be assessed to determine if the trial is stopped before the Phase II portion.	
				Objective response rate	

Discussion and prospects

The use of PD-1 and PD-L1 inhibitors in the treatment of malignant urinary system tumors presents significant challenges due to the development of resistance that needs to be overcome. Central to this issue is the TME, which includes diverse cell types such as TAMs, TILs, and fibroblasts [33, 157]. These components alter immune dynamics by secreting cytokines and growth factors, influencing the effectiveness of PD-1/PD-L1 inhibitors. Resistance also stems from specific genetic mutations and aberrant signaling pathways. For instance, mutations in JAK1/2 genes can disrupt IFN-γ signaling, enabling tumor cells to evade immune surveillance [158]. Furthermore, dysregulated activation of the PI3K/AKT/mTOR pathway is associated with resistance to PD-1/PD-L1 inhibitors. The regulation of PD-L1 expression plays a pivotal role in determining the efficacy of PD-1/PD-L1 inhibitors. Tumor cells can also modulate PD-L1 expression through genomic and epigenomic mechanisms [159]. Epigenetic modifications such as DNA methylation and histone alterations enable tumor cells to reduce PD-L1 gene expression, thereby enhancing resistance to inhibitor therapies. Additionally, tumors employ various strategies to evade immune detection, including elevated expression of immune checkpoint molecules, secretion of immunosuppressive factors, and stimulation of immune-suppressive cell proliferation [52, 160]. Collectively, these mechanisms contribute to resistance against PD-1/PD-L1 inhibitors. Combining PD-1/PD-L1 inhibitors with other ICIs represents a promising strategy to bolster anti-tumor immune responses and surmount resistance encountered with single-agent therapies. By targeting multiple immune regulatory pathways simultaneously, combination therapies hold the potential to enhance treatment outcomes in patients with urinary system malignancies.

Combining PD-1/PD-L1 inhibitors with various treatment modalities enhances anti-tumor effects in urinary system cancers by leveraging complementary mechanisms. Radiotherapy induces tumor cell apoptosis and releases antigens, priming the immune system to recognize tumors, synergizing with PD-1/PD-L1 inhibitors [52, 161]. Emerging therapies like cancer vaccines, OVs, and CAR-T cell therapy boost immune responses through distinct mechanisms, such as direct tumor cell lysis and antigen release [88, 162]. Targeted therapies specific to the TME, such as TAM inhibitors, anti-angiogenics, and TGF-β pathway inhibitors, reduce immunosuppression in the TME, enhancing PD-1/PD-L1 inhibitor efficacy [163]. Gene editing tools like CRISPR/Cas9 address resistance by manipulating genes responsible, restoring immune recognition of tumors [164]. Epigenetic regulators like DNA methyltransferase inhibitors (DNMTi) and histone deacetylase inhibitors (HDACi) alter gene expression, sensitizing tumors to immune attack and reversing immune suppression [50, 165]. These approaches collectively overcome resistance, offering avenues to improve clinical outcomes with PD-1/PD-L1 inhibitors in urinary system cancers.

Personalized medicine offers significant promise in treating urinary system tumors by enhancing treatment efficacy through tailored therapeutic approaches. Genomic sequencing identifies specific mutations, gene expression patterns, and genomic instability in tumors, crucial for predicting responses to PD-1 and PD-L1 ICI. Proteomic analysis examines protein expression and modifications in tumors and their microenvironment, providing insights into tumor biology and potential targets for therapy. Understanding PD-L1 expression and its regulation in the TME optimizes combination immunotherapy strategies. High-throughput screening technologies like single-cell sequencing and mass spectrometry provide detailed insights into tumor heterogeneity and the immune microenvironment, guiding precise treatment planning to improve patient outcomes. Integrating genomic and proteomic data enables personalized treatment regimens tailored to individual molecular profiles, prioritizing PD-1/PD-L1 inhibitors for patients with high PD-L1 expression and considering combined therapies for those with specific mutations or other molecular characteristics.

Liquid biopsy technology, a non-invasive method, analyzes circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in blood to monitor real-time genomic changes and resistance mechanisms in tumors. This facilitates prompt adjustments to treatment plans, assessment of treatment efficacy, and early detection of recurrence. Personalized therapy requires consideration of the patient’s immune microenvironment, including immune cell infiltration, cytokine expression levels, and immune-suppressive conditions within the TME, all of which significantly impact the effectiveness of PD-1/PD-L1 inhibitors. By comprehensively analyzing these factors, treatment responses can be accurately predicted, optimizing therapeutic strategies. Despite substantial progress in PD-1/PD-L1 inhibitors for treating urinary system cancers, many patients remain unresponsive to current therapies. Hence, attention is increasingly focused on developing next-generation ICIs targeting novel checkpoints. Ongoing research explores new targets such as CTLA-4, TIM-3, LAG-3, and others. CTLA-4 inhibitors, like Ipilimumab, show synergistic effects when combined with PD-1/PD-L1 inhibitors, and was recently approved for advanced RCC treatment. Clinical trials are evaluating the safety and efficacy of inhibitors against other emerging targets such as TIM-3 and LAG-3. Additionally, novel immune therapies like bispecific antibodies and fusion proteins are emerging. These agents simultaneously target multiple immune checkpoints, effectively reversing tumor immune suppression and enhancing treatment outcomes. For example, bispecific antibodies can inhibit both PD-1 and LAG-3, thereby bolstering anti-tumor immune responses. Preclinical studies have demonstrated that LAG-3 inhibitors exhibit significant anti-tumor activity and synergistic effects in combination with PD-1 inhibitors [166–168]. Early clinical trials further validate the safety and efficacy of these drugs in patients, supporting their potential therapeutic role. Various combination therapies involving ICIs have also shown promising prospects in early clinical trials. The future of treating urological cancers will likely embrace personalized medicine approaches integrating genomic and proteomic analyses, alongside tailored therapies aligned with individual patient profiles.

The heterogeneity of urological malignancies substantially impacts the effectiveness of PD-L1 and PD-1 blockade therapies [41, 169, 170]. Although these ICIs have demonstrated impressive efficacy in the treatment of BCa and RCC, their utilization in PCa has yet to achieve widespread endorsement. This discrepancy is primarily attributed to the lower immunogenicity of PCa, characterized by a paucity of neoantigens in the TME, thereby impeding the immune system’s ability to identify and eliminate malignant cells (Fig. 7). Conversely, BCa and RCC typically exhibit a higher mutational burden and a more diverse antigenic repertoire, enhancing the responsiveness to ICIs. In BCa and RCC, anti-PD-L1 and PD-1 therapies function by inhibiting the PD-1/PD-L1 axis, thus relieving T cell suppression and augmenting the immune response against neoplasm. However, due to the low immunogenicity and intricate TME of PCa, the response to immunotherapy is often suboptimal. Research indicates that the TME in PCa is infiltrated by a significant number of immunosuppressive cells, such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), which secrete inhibitory cytokines to diminish the anti-tumor immune response. Moreover, while certain immunotherapeutic agents have shown substantial efficacy in BCa and RCC, their effectiveness is not uniform across all urological cancers. Analyzing their mechanisms of action suggests that this variability may be linked to the distinct microenvironmental characteristics, mutational landscapes, and immune evasion strategies inherent to different tumor types. Therefore, when evaluating the application of immunotherapy in urological malignancies, it is crucial to consider the heterogeneity of these tumors and tailor therapeutic approaches accordingly. A comprehensive understanding of these differences can facilitate the optimization of treatment protocols, ultimately enhancing patient survival rates and quality of life.

Fig. 7 Mutational loads across different tumor types correlate with tumor immunogenicity.Reproduced with permission [171]. Copyright 2018, Springer Nature

Anti-PD-1 and anti-PD-L1 immunotherapies have demonstrated potential in managing urological malignancies, notably BCa and RCC. Nevertheless, their therapeutic efficacy in these cancers is comparatively modest, particularly when juxtaposed with malignancies such as melanoma. PCa exemplifies this disparity, exhibiting lower clinical response rates. The inherent heterogeneity of urological neoplasms and the intricate TME present significant obstacles that attenuate the effectiveness of these therapies. Specifically, the low immunogenicity and immunosuppressive milieu of PCa impede the therapeutic impact of anti-PD-1 and anti-PD-L1 agents, resulting in suboptimal clinical outcomes. To circumvent these challenges, researchers are intensively investigating the potential of combinatory therapeutic strategies. Integrating ICIs with other treatment modalities, including chemotherapy, radiotherapy, targeted therapies, and additional forms of immunotherapy, may potentiate immune responses and augment therapeutic efficacy. For instance, clinical studies have indicated that the concurrent administration of anti-PD-1/PD-L1 agents with platinum-based chemotherapy significantly enhances overall response rates and extends survival in patients with urothelial carcinoma. Moreover, emerging clinical trials are focusing on novel combinatorial approaches to bolster the effectiveness of these therapies. These strategies encompass the integration of immunotherapy with cancer vaccines, adoptive cellular therapies, or other immunomodulatory agents, aiming to robustly activate the patient’s immune system for a more efficacious antitumor response. In summary, although anti-PD-1 and anti-PD-L1 therapies encounter limitations in the treatment of urological malignancies, their therapeutic potential can be further realized through rational combination strategies and innovative clinical trial designs, thereby providing more efficacious treatment avenues for patients.

Conclusion

In this detailed review, we describe the crucial function of the PD-1/PD-L1 pathway in urological malignancies, including BCa, RCC, and PCa. Aberrant PD-1/PD-L1 signaling has been recognized as a significant factor in these cancers, facilitating immune evasion, tumor progression, and metastasis. Both preclinical and clinical studies have repeatedly demonstrated that inhibiting PD-1/PD-L1 interactions boosts anti-tumor immune responses and effectively suppresses tumor growth. These results highlight the therapeutic promise of PD-1/PD-L1 inhibitors in urological cancers.

Acknowledgements

We thank the generous support of Liaoning Cancer Hospital & Institute (Shenyang) and Dalian University of Technology(Dalian).

Author contributions

Original draft preparation, allocation, revision, and editing: Qiang Liu, Yujing Guan and Shenglong Li. All authors have read and agreed to the published version of the manuscript.

Funding

None.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

None.

Consent for publication

None.

Competing interests

The authors declare no competing interests.

Abbreviations

PD-1 Programmed death receptor 1

PD-L1 Programmed death ligand-1

BCa Bladder cancer

RCC Renal cell carcinoma

PCa Prostate cancer

NMIBC Non-muscle invasive bladder cancer

MIBC Muscle invasive bladder cancer

ccRCC Clear cell renal cell carcinoma

mCRPC Metastatic castration-resistant prostate cancer

NK Natural killer

ITIM Immunoreceptor tyrosine-based inhibitory motif

ITSM immunoreceptor tyrosine-based switch motif

APCs Antigen-presenting cells

TCR T cell receptor

NF-κB Nuclear factor kappa B

AP-1 Activator protein 1

IRF Interferon regulatory factors

HDACs Histone deacetylases

IFN-γ Including interferon-gamma

TGF-β Transforming growth factor-beta

miRNAs MicroRNAs

TME Tumor microenvironment

HIF-1α Hypoxia-inducible factor 1-alpha

TNF-α Tumor necrosis factor-alpha

DCs Dendritic cells

DCs Dendritic cells

Tregs Regulatory T cells

Teffs Effector T cells

CTLA-4 Cytotoxic T-lymphocyte-associated protein 4

TIM-3 T-cell immunoglobulin and mucin domain-containing protein 3

LAG-3 Lymphocyte activation gene-3

MHC Major histocompatibility complex

YY1 Yin Yang 1

EMSA Electrophoretic mobility shift assay

TFEB Transcription factor EB

TFE3 Transcription factor E3

HIF2α Hypoxia-inducible factor 2-alpha

PTMs Post-transcriptional modifications

ISG15 Interferon-induced protein 15

FGFR3 Fibroblast Growth Factor Receptor 3

TGFβ1 Transforming growth factor beta 1

EVs Extracellular vesicles

pRB Phosphorylated retinoblastoma protein

HnRNP L Heterogeneous nuclear ribonucleoprotein L

TAMs Tumor-associated macrophages

PKM2 Pyruvate kinase M2

AR Androgen receptor

MTHFD2 Methylenetetrahydrofolate dehydrogenase 2

RRM2 Ribonucleotide Reductase Regulatory Subunit M2

NFAT1 Nuclear factor of activated T cells 1

TOPK T-LAK cell-originated Protein Kinase

EGFR Epidermal Growth Factor Receptor

GHITM Growth hormone-inducible transmembrane protein

GM-CSF Granulocyte-Macrophage Colony-Stimulating Factor

BTK Bruton’s tyrosine kinase

TIGIT T-cell immunoglobulin and ITIM domain

BCa Breast cancer

OXP Oxaliplatin

FGFR Fibroblast Growth Factor Receptor

αKG Alpha-ketoglutarate

TCA Tricarboxylic acid

ORR Objective response rate

TILs Tumor-infiltrating lymphocytes

Ovs Oncolytic viruses

DNMTi DNA methyltransferase inhibitors

HDACi Histone deacetylase inhibitors

ICI Immune checkpoint inhibitors

The original online version of this article was revised: Following publication of the original article [1], the author reported that the published PDF version is incorrect as the information such as "(See Fig. 5)", "(Fig. 4; Table 3)", and "[170]" need to be removed and updated accordingly as shown in the correction article 10.1186/s12943-024-02121-9.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Change history

9/14/2024

A Correction to this paper has been published: 10.1186/s12943-024-02121-9
==== Refs
References

1. Ben-David R, Galsky MD, Sfakianos JP. Novel bladder-sparing approaches in patients with muscle-invasive bladder cancer. Trends Mol Med, (2024).
2. Guo CC, Lee S, Lee JG, Chen H, Zaleski M, Choi W, McConkey DJ, Wei P, Czerniak B. Molecular profile of bladder cancer progression to clinically aggressive subtypes. Nat Rev Urol, (2024).
3. Park JS Lee ME Kim J Oh K Lee N Jung M Jang WS Ham WS PD-1 inhibitor plus oncolytic vaccinia virus is a safe and effective treatment option for metastatic renal cell carcinoma Cancer Cell Int 2024 24 50 10.1186/s12935-024-03238-z 38291394
Park JS, Lee ME, Kim J, Oh K, Lee N, Jung M, Jang WS, Ham WS. PD-1 inhibitor plus oncolytic vaccinia virus is a safe and effective treatment option for metastatic renal cell carcinoma. Cancer Cell Int. 2024;24:50.38291394 10.1186/s12935-024-03238-z
4. Grobet-Jeandin E Lenfant L Pinar U Parra J Mozer P Renard-Penna R Thibault C Roupret M Seisen T Management of patients with muscle-invasive bladder cancer with clinical evidence of pelvic lymph node metastases Nat Rev Urol 2024 21 339 56 10.1038/s41585-023-00842-y 38297079
Grobet-Jeandin E, Lenfant L, Pinar U, Parra J, Mozer P, Renard-Penna R, Thibault C, Roupret M, Seisen T. Management of patients with muscle-invasive bladder cancer with clinical evidence of pelvic lymph node metastases. Nat Rev Urol. 2024;21:339–56.38297079 10.1038/s41585-023-00842-y
5. Alfred Witjes J Max Bruins H Carrion A Cathomas R Comperat E Efstathiou JA Fietkau R Gakis G Lorch A Martini A Mertens LS Meijer RP Milowsky MI Neuzillet Y Panebianco V Redlef J Rink M Rouanne M Thalmann GN Saebjornsen S Veskimae E van der Heijden AG European Association of Urology Guidelines on muscle-invasive and metastatic bladder Cancer: Summary of the 2023 guidelines Eur Urol 2024 85 17 31 10.1016/j.eururo.2023.08.016 37858453
Alfred Witjes J, Max Bruins H, Carrion A, Cathomas R, Comperat E, Efstathiou JA, Fietkau R, Gakis G, Lorch A, Martini A, Mertens LS, Meijer RP, Milowsky MI, Neuzillet Y, Panebianco V, Redlef J, Rink M, Rouanne M, Thalmann GN, Saebjornsen S, Veskimae E, van der Heijden AG. European Association of Urology Guidelines on muscle-invasive and metastatic bladder Cancer: Summary of the 2023 guidelines. Eur Urol. 2024;85:17–31.37858453 10.1016/j.eururo.2023.08.016
6. Maas M Todenhofer T Black PC Urine biomarkers in bladder cancer - current status and future perspectives Nat Rev Urol 2023 20 597 614 10.1038/s41585-023-00773-8 37225864
Maas M, Todenhofer T, Black PC. Urine biomarkers in bladder cancer - current status and future perspectives. Nat Rev Urol. 2023;20:597–614.37225864 10.1038/s41585-023-00773-8
7. Jubber I Ong S Bukavina L Black PC Comperat E Kamat AM Kiemeney L Lawrentschuk N Lerner SP Meeks JJ Moch H Necchi A Panebianco V Sridhar SS Znaor A Catto JWF Cumberbatch MG Epidemiology of bladder Cancer in 2023: a systematic review of risk factors Eur Urol 2023 84 176 90 10.1016/j.eururo.2023.03.029 37198015
Jubber I, Ong S, Bukavina L, Black PC, Comperat E, Kamat AM, Kiemeney L, Lawrentschuk N, Lerner SP, Meeks JJ, Moch H, Necchi A, Panebianco V, Sridhar SS, Znaor A, Catto JWF, Cumberbatch MG. Epidemiology of bladder Cancer in 2023: a systematic review of risk factors. Eur Urol. 2023;84:176–90.37198015 10.1016/j.eururo.2023.03.029
8. Dyrskjot L Hansel DE Efstathiou JA Knowles MA Galsky MD Teoh J Theodorescu D Bladder cancer Nat Rev Dis Primers 2023 9 58 10.1038/s41572-023-00468-9 37884563
Dyrskjot L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J, Theodorescu D. Bladder cancer. Nat Rev Dis Primers. 2023;9:58.37884563 10.1038/s41572-023-00468-9
9. Lopez-Beltran A Cookson MS Guercio BJ Cheng L Advances in diagnosis and treatment of bladder cancer BMJ 2024 384 e076743 10.1136/bmj-2023-076743 38346808
Lopez-Beltran A, Cookson MS, Guercio BJ, Cheng L. Advances in diagnosis and treatment of bladder cancer. BMJ. 2024;384:e076743.38346808 10.1136/bmj-2023-076743
10. Matuszczak M, Salagierski M. Diagnostic and prognostic potential of biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in bladder cancers. Int J Mol Sci, 21 (2020).
11. Matuszczak M, Schalken JA, Salagierski M. Prostate Cancer Liquid Biopsy Biomarkers’ Clinical Utility in Diagnosis and Prognosis. Cancers (Basel), 13 (2021).
12. Matuszczak M, Kiljanczyk A, Salagierski M. A liquid biopsy in bladder Cancer-The Current Landscape in urinary biomarkers. Int J Mol Sci, 23 (2022).
13. Shkolyar E, Zhou SR, Carlson CJ, Chang S, Laurie MA, Xing L, Bowden AK, Liao JC. Optimizing cystoscopy and TURBT: enhanced imaging and artificial intelligence. Nat Rev Urol, (2024).
14. Matuszczak M, Kiljanczyk A, Salagierski M. The Role of Focal Therapy and Active Surveillance for Small Renal Mass Therapy, Biomedicines, 10 (2022).
15. Chen J Huang CP Quan C Zu X Ou Z Tsai YC Messing E Yeh S Chang C The androgen receptor in bladder cancer Nat Rev Urol 2023 20 560 74 10.1038/s41585-023-00761-y 37072491
Chen J, Huang CP, Quan C, Zu X, Ou Z, Tsai YC, Messing E, Yeh S, Chang C. The androgen receptor in bladder cancer. Nat Rev Urol. 2023;20:560–74.37072491 10.1038/s41585-023-00761-y
16. Cotta BH Choueiri TK Cieslik M Ghatalia P Mehra R Morgan TM Palapattu GS Shuch B Vaishampayan U Van Allen E Ari Hakimi A Salami SS Current Landscape of genomic biomarkers in Clear Cell Renal Cell Carcinoma Eur Urol 2023 84 166 75 10.1016/j.eururo.2023.04.003 37085424
Cotta BH, Choueiri TK, Cieslik M, Ghatalia P, Mehra R, Morgan TM, Palapattu GS, Shuch B, Vaishampayan U, Van Allen E, Ari Hakimi A, Salami SS. Current Landscape of genomic biomarkers in Clear Cell Renal Cell Carcinoma. Eur Urol. 2023;84:166–75.37085424 10.1016/j.eururo.2023.04.003
17. Mao X, Wang G, Wang Z, Duan C, Wu X, Xu H. Theranostic lipid nanoparticles for renal cell carcinoma. Adv Mater, (2023) e2306246.
18. Motzer RJ Rane PP Saretsky TL Pawar D Martin Nguyen A Sundaram M Burgents J Pandey R Rudell K Patient-reported Outcome Measurement and reporting for patients with Advanced Renal Cell Carcinoma: a systematic literature review Eur Urol 2023 84 406 17 10.1016/j.eururo.2023.07.006 37550153
Motzer RJ, Rane PP, Saretsky TL, Pawar D, Martin Nguyen A, Sundaram M, Burgents J, Pandey R, Rudell K. Patient-reported Outcome Measurement and reporting for patients with Advanced Renal Cell Carcinoma: a systematic literature review. Eur Urol. 2023;84:406–17.37550153 10.1016/j.eururo.2023.07.006
19. Catalano M Procopio G Sepe P Santoni M Sessa F Villari D Nesi G Roviello G Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: trick or treat? Pharmacol Ther 2023 249 108499 10.1016/j.pharmthera.2023.108499 37479037
Catalano M, Procopio G, Sepe P, Santoni M, Sessa F, Villari D, Nesi G, Roviello G. Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: trick or treat? Pharmacol Ther. 2023;249:108499.37479037 10.1016/j.pharmthera.2023.108499
20. Wang Y Suarez ER Kastrunes G de Campos NSP Abbas R Pivetta RS Murugan N Chalbatani GM D’Andrea V Marasco WA Evolution of cell therapy for renal cell carcinoma Mol Cancer 2024 23 8 10.1186/s12943-023-01911-x 38195534
Wang Y, Suarez ER, Kastrunes G, de Campos NSP, Abbas R, Pivetta RS, Murugan N, Chalbatani GM, D’Andrea V, Marasco WA. Evolution of cell therapy for renal cell carcinoma. Mol Cancer. 2024;23:8.38195534 10.1186/s12943-023-01911-x
21. Venkatesh N Martini A McQuade JL Msaouel P Hahn AW Obesity and renal cell carcinoma: Biological mechanisms and perspectives Semin Cancer Biol 2023 94 21 33 10.1016/j.semcancer.2023.06.001 37286114
Venkatesh N, Martini A, McQuade JL, Msaouel P, Hahn AW. Obesity and renal cell carcinoma: Biological mechanisms and perspectives. Semin Cancer Biol. 2023;94:21–33.37286114 10.1016/j.semcancer.2023.06.001
22. Weiner AB, Kakani P, Armstrong AJ, Bossi A, Cornford P, Feng F, Kanabur P, Karnes RJ, McKay RR, Morgan TM, Schaeffer EM, Shore N, Tree AC, Spratt DE. Risk stratification of patients with recurrence after primary treatment for prostate Cancer. A Systematic Review, Eur Urol; 2024.
23. Jiao J Zhang J Wen W Qin W Chen X Prostate-specific membrane antigen-targeted surgery in prostate cancer: accurate identification, real-time diagnosis, and precise resection Theranostics 2024 14 2736 56 10.7150/thno.95039 38773975
Jiao J, Zhang J, Wen W, Qin W, Chen X. Prostate-specific membrane antigen-targeted surgery in prostate cancer: accurate identification, real-time diagnosis, and precise resection. Theranostics. 2024;14:2736–56.38773975 10.7150/thno.95039
24. Hussain M Fizazi K Shore ND Heidegger I Smith MR Tombal B Saad F Metastatic hormone-sensitive prostate Cancer and combination treatment outcomes: a review JAMA Oncol 2024 10 807 20 10.1001/jamaoncol.2024.0591 38722620
Hussain M, Fizazi K, Shore ND, Heidegger I, Smith MR, Tombal B, Saad F. Metastatic hormone-sensitive prostate Cancer and combination treatment outcomes: a review. JAMA Oncol. 2024;10:807–20.38722620 10.1001/jamaoncol.2024.0591
25. Cao PHA, Dominic A, Lujan FE, Senthilkumar S, Bhattacharya PK, Frigo DE, Subramani E. Unlocking ferroptosis in prostate cancer - the road to novel therapies and imaging markers. Nat Rev Urol, (2024).
26. Zhu L Pan J Mou W Deng L Zhu Y Wang Y Pareek G Hyams E Carneiro BA Hadfield MJ El-Deiry WS Yang T Tan T Tong T Ta N Zhu Y Gao Y Lai Y Cheng L Chen R Xue W Harnessing artificial intelligence for prostate cancer management Cell Rep Med 2024 5 101506 10.1016/j.xcrm.2024.101506 38593808
Zhu L, Pan J, Mou W, Deng L, Zhu Y, Wang Y, Pareek G, Hyams E, Carneiro BA, Hadfield MJ, El-Deiry WS, Yang T, Tan T, Tong T, Ta N, Zhu Y, Gao Y, Lai Y, Cheng L, Chen R, Xue W. Harnessing artificial intelligence for prostate cancer management. Cell Rep Med. 2024;5:101506.38593808 10.1016/j.xcrm.2024.101506
27. Chen H Pang B Zhou C Han M Gong J Li Y Jiang J Prostate cancer-derived small extracellular vesicle proteins: the hope in diagnosis, prognosis, and therapeutics J Nanobiotechnol 2023 21 480 10.1186/s12951-023-02219-0
Chen H, Pang B, Zhou C, Han M, Gong J, Li Y, Jiang J. Prostate cancer-derived small extracellular vesicle proteins: the hope in diagnosis, prognosis, and therapeutics. J Nanobiotechnol. 2023;21:480.10.1186/s12951-023-02219-0
28. Gebrael G Fortuna GG Sayegh N Swami U Agarwal N Advances in the treatment of metastatic prostate cancer Trends Cancer 2023 9 840 54 10.1016/j.trecan.2023.06.009 37442702
Gebrael G, Fortuna GG, Sayegh N, Swami U, Agarwal N. Advances in the treatment of metastatic prostate cancer. Trends Cancer. 2023;9:840–54.37442702 10.1016/j.trecan.2023.06.009
29. Lin X Kang K Chen P Zeng Z Li G Xiong W Yi M Xiang B Regulatory mechanisms of PD-1/PD-L1 in cancers Mol Cancer 2024 23 108 10.1186/s12943-024-02023-w 38762484
Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, Yi M, Xiang B. Regulatory mechanisms of PD-1/PD-L1 in cancers. Mol Cancer. 2024;23:108.38762484 10.1186/s12943-024-02023-w
30. Li Y Sharma A Schmidt-Wolf IGH Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer Mol Cancer 2024 23 80 10.1186/s12943-023-01926-4 38659003
Li Y, Sharma A, Schmidt-Wolf IGH. Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer. Mol Cancer. 2024;23:80.38659003 10.1186/s12943-023-01926-4
31. Groeger S, Meyle J. The role of programmed death receptor (PD-)1/PD-ligand (L)1 in periodontitis and cancer, Periodontol 2000, (2024).
32. Hashimoto M Ramalingam SS Ahmed R Harnessing CD8 T cell responses using PD-1-IL-2 combination therapy Trends Cancer 2024 10 332 46 10.1016/j.trecan.2023.11.008 38129234
Hashimoto M, Ramalingam SS, Ahmed R. Harnessing CD8 T cell responses using PD-1-IL-2 combination therapy. Trends Cancer. 2024;10:332–46.38129234 10.1016/j.trecan.2023.11.008
33. Zhang H Liu L Liu J Dang P Hu S Yuan W Sun Z Liu Y Wang C Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers Mol Cancer 2023 22 58 10.1186/s12943-023-01725-x 36941614
Zhang H, Liu L, Liu J, Dang P, Hu S, Yuan W, Sun Z, Liu Y, Wang C. Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers. Mol Cancer. 2023;22:58.36941614 10.1186/s12943-023-01725-x
34. Pei L Liu Y Liu L Gao S Gao X Feng Y Sun Z Zhang Y Wang C Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers Mol Cancer 2023 22 29 10.1186/s12943-023-01731-z 36759842
Pei L, Liu Y, Liu L, Gao S, Gao X, Feng Y, Sun Z, Zhang Y, Wang C. Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers. Mol Cancer. 2023;22:29.36759842 10.1186/s12943-023-01731-z
35. Sordo-Bahamonde C Lorenzo-Herrero S Granda-Díaz R Martínez-Pérez A Aguilar-García C Rodrigo JP García-Pedrero JM Gonzalez S Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy Mol Cancer 2023 22 142 10.1186/s12943-023-01845-4 37649037
Sordo-Bahamonde C, Lorenzo-Herrero S, Granda-Díaz R, Martínez-Pérez A, Aguilar-García C, Rodrigo JP, García-Pedrero JM, Gonzalez S. Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy. Mol Cancer. 2023;22:142.37649037 10.1186/s12943-023-01845-4
36. Liu S Wang H Shao X Chen H Chao S Zhang Y Gao Z Yao Q Zhang P Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy J Nanobiotechnol 2023 21 207 10.1186/s12951-023-01966-4
Liu S, Wang H, Shao X, Chen H, Chao S, Zhang Y, Gao Z, Yao Q, Zhang P. Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy. J Nanobiotechnol. 2023;21:207.10.1186/s12951-023-01966-4
37. Pang K Shi ZD Wei LY Dong Y Ma YY Wang W Wang GY Cao MY Dong JJ Chen YA Zhang P Hao L Xu H Pan D Chen ZS Han CH Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade Drug Resist Updat 2023 66 100907 10.1016/j.drup.2022.100907 36527888
Pang K, Shi ZD, Wei LY, Dong Y, Ma YY, Wang W, Wang GY, Cao MY, Dong JJ, Chen YA, Zhang P, Hao L, Xu H, Pan D, Chen ZS, Han CH. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade. Drug Resist Updat. 2023;66:100907.36527888 10.1016/j.drup.2022.100907
38. Laba S Mallett G Amarnath S The depths of PD-1 function within the tumor microenvironment beyond CD8(+) T cells Semin Cancer Biol 2022 86 1045 55 10.1016/j.semcancer.2021.05.022 34048897
Laba S, Mallett G, Amarnath S. The depths of PD-1 function within the tumor microenvironment beyond CD8(+) T cells. Semin Cancer Biol. 2022;86:1045–55.34048897 10.1016/j.semcancer.2021.05.022
39. Chu X Tian W Wang Z Zhang J Zhou R Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: mechanisms and clinical trials Mol Cancer 2023 22 93 10.1186/s12943-023-01800-3 37291608
Chu X, Tian W, Wang Z, Zhang J, Zhou R. Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: mechanisms and clinical trials. Mol Cancer. 2023;22:93.37291608 10.1186/s12943-023-01800-3
40. Wu M Huang Q Xie Y Wu X Ma H Zhang Y Xia Y Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation J Hematol Oncol 2022 15 24 10.1186/s13045-022-01242-2 35279217
Wu M, Huang Q, Xie Y, Wu X, Ma H, Zhang Y, Xia Y. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol. 2022;15:24.35279217 10.1186/s13045-022-01242-2
41. Yi M Zheng X Niu M Zhu S Ge H Wu K Combination strategies with PD-1/PD-L1 blockade: current advances and future directions Mol Cancer 2022 21 28 10.1186/s12943-021-01489-2 35062949
Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21:28.35062949 10.1186/s12943-021-01489-2
42. Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. NCCN Guidelines(R) Insights: Bladder Cancer, Version 2.2022, J Natl Compr Canc Netw, 20 (2022) 866–878.
43. Sperger JM Emamekhoo H McKay RR Stahlfeld CN Singh A Chen XE Kwak L Gilsdorf CS Wolfe SK Wei XX Silver R Zhang Z Morris MJ Bubley G Feng FY Scher HI Rathkopf D Dehm SM Choueiri TK Halabi S Armstrong AJ Wyatt AW Taplin ME Zhao SG Lang JM Prospective evaluation of clinical outcomes using a Multiplex Liquid Biopsy Targeting Diverse Resistance mechanisms in metastatic prostate Cancer J Clin Oncol 2021 39 2926 37 10.1200/JCO.21.00169 34197212
Sperger JM, Emamekhoo H, McKay RR, Stahlfeld CN, Singh A, Chen XE, Kwak L, Gilsdorf CS, Wolfe SK, Wei XX, Silver R, Zhang Z, Morris MJ, Bubley G, Feng FY, Scher HI, Rathkopf D, Dehm SM, Choueiri TK, Halabi S, Armstrong AJ, Wyatt AW, Taplin ME, Zhao SG, Lang JM. Prospective evaluation of clinical outcomes using a Multiplex Liquid Biopsy Targeting Diverse Resistance mechanisms in metastatic prostate Cancer. J Clin Oncol. 2021;39:2926–37.34197212 10.1200/JCO.21.00169
44. Matuszczak M, Kiljanczyk A, Salagierski M. Surgical Approach in metastatic renal cell carcinoma: a Literature Review. Cancers (Basel), 15 (2023).
45. Marvaso G, Jereczek-Fossa BA, Zaffaroni M, Vincini MG, Corrao G, Andratschke N, Balagamwala EH, Bedke J, Blanck O, Capitanio U, Correa RJM, De Meerleer G, Franzese C, Gaeta A, Gandini S, Garibaldi C, Gerszten PC, Gillessen S, Grubb WR, Guckenberger M, Hannan R, Jhaveri PM, Josipovic M, Kerkmeijer LGW, Lehrer EJ, Lindskog M, Louie AV, Nguyen QN, Ost P, Palma DA, Procopio G, Rossi M, Staehler M, Tree AC, Tsang YM, Van As N, Zaorsky NG, Zilli T, Pasquier D, Siva S. Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma-a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology, Lancet Oncol, 25 (2024) e193-e204.
46. Bamias A Davis ID Galsky MD Arranz JA Kikuchi E Grande E Del Muro XG Park SH De Giorgi U Alekseev B Mencinger M Izumi K Schutz FA Puente J Li JR Panni S Gumus M Ozguroglu M Mariathasan S Poloz Y Bene-Tchaleu F Lee C Bernhard S De Santis M Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study Lancet Oncol 2024 25 46 61 10.1016/S1470-2045(23)00539-9 38101431
Bamias A, Davis ID, Galsky MD, Arranz JA, Kikuchi E, Grande E, Del Muro XG, Park SH, De Giorgi U, Alekseev B, Mencinger M, Izumi K, Schutz FA, Puente J, Li JR, Panni S, Gumus M, Ozguroglu M, Mariathasan S, Poloz Y, Bene-Tchaleu F, Lee C, Bernhard S, De Santis M. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study. Lancet Oncol. 2024;25:46–61.38101431 10.1016/S1470-2045(23)00539-9
47. Powles T Bellmunt J Comperat E De Santis M Huddart R Loriot Y Necchi A Valderrama BP Ravaud A Shariat SF Szabados B van der Heijden MS Gillessen S E.G.C.E.a. clinicalguidelines@esmo.org, bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Ann Oncol 2022 33 244 58 10.1016/j.annonc.2021.11.012 34861372
Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP, Ravaud A, Shariat SF, Szabados B, van der Heijden MS, Gillessen S. E.G.C.E.a. clinicalguidelines@esmo.org, bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:244–58.34861372 10.1016/j.annonc.2021.11.012
48. Islam MK Stanslas J Peptide-based and small molecule PD-1 and PD-L1 pharmacological modulators in the treatment of cancer Pharmacol Ther 2021 227 107870 10.1016/j.pharmthera.2021.107870 33895183
Islam MK, Stanslas J. Peptide-based and small molecule PD-1 and PD-L1 pharmacological modulators in the treatment of cancer. Pharmacol Ther. 2021;227:107870.33895183 10.1016/j.pharmthera.2021.107870
49. Patsoukis N, Wang Q, Strauss L, Boussiotis VA. Revisiting the PD-1 pathway. Sci Adv, 6 (2020).
50. Chen X Pan X Zhang W Guo H Cheng S He Q Yang B Ding L Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses Acta Pharm Sin B 2020 10 723 33 10.1016/j.apsb.2019.09.006 32528824
Chen X, Pan X, Zhang W, Guo H, Cheng S, He Q, Yang B, Ding L. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses. Acta Pharm Sin B. 2020;10:723–33.32528824 10.1016/j.apsb.2019.09.006
51. Moser JC Hu-Lieskovan S Mechanisms of resistance to PD-1 checkpoint blockade Drugs 2020 80 459 65 10.1007/s40265-020-01270-7 32096021
Moser JC, Hu-Lieskovan S. Mechanisms of resistance to PD-1 checkpoint blockade. Drugs. 2020;80:459–65.32096021 10.1007/s40265-020-01270-7
52. Yamaguchi H, Hsu JM, Sun L, Wang SC, Hung MC. Advances and prospects of biomarkers for immune checkpoint inhibitors. Cell Rep Med, (2024) 101621.
53. Sun Q Hong Z Zhang C Wang L Han Z Ma D Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends Signal Transduct Target Ther 2023 8 320 10.1038/s41392-023-01522-4 37635168
Sun Q, Hong Z, Zhang C, Wang L, Han Z, Ma D. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduct Target Ther. 2023;8:320.37635168 10.1038/s41392-023-01522-4
54. Cai L Li Y Tan J Xu L Li Y Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy J Hematol Oncol 2023 16 101 10.1186/s13045-023-01499-1 37670328
Cai L, Li Y, Tan J, Xu L, Li Y. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16:101.37670328 10.1186/s13045-023-01499-1
55. Pulanco MC Madsen AT Tanwar A Corrigan DT Zang X Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies Cell Mol Immunol 2023 20 694 713 10.1038/s41423-023-01019-8 37069229
Pulanco MC, Madsen AT, Tanwar A, Corrigan DT, Zang X. Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies. Cell Mol Immunol. 2023;20:694–713.37069229 10.1038/s41423-023-01019-8
56. Lin Q Wang X Hu Y The opportunities and challenges in immunotherapy: insights from the regulation of PD-L1 in cancer cells Cancer Lett 2023 569 216318 10.1016/j.canlet.2023.216318 37454966
Lin Q, Wang X, Hu Y. The opportunities and challenges in immunotherapy: insights from the regulation of PD-L1 in cancer cells. Cancer Lett. 2023;569:216318.37454966 10.1016/j.canlet.2023.216318
57. Kiriyama Y, Nochi H. Regulation of PD-L1 expression by Nuclear receptors. Int J Mol Sci, 24 (2023).
58. Beenen AC, Sauerer T, Schaft N, Dorrie J. Beyond Cancer: regulation and function of PD-L1 in Health and Immune-Related diseases. Int J Mol Sci, 23 (2022).
59. Liu Z Yu X Xu L Li Y Zeng C Current insight into the regulation of PD-L1 in cancer Exp Hematol Oncol 2022 11 44 10.1186/s40164-022-00297-8 35907881
Liu Z, Yu X, Xu L, Li Y, Zeng C. Current insight into the regulation of PD-L1 in cancer. Exp Hematol Oncol. 2022;11:44.35907881 10.1186/s40164-022-00297-8
60. Nihira NT Miki Y Regulation of intrinsic functions of PD-L1 by post-translational modification in tumors Front Oncol 2022 12 825284 10.3389/fonc.2022.825284 35402280
Nihira NT, Miki Y. Regulation of intrinsic functions of PD-L1 by post-translational modification in tumors. Front Oncol. 2022;12:825284.35402280 10.3389/fonc.2022.825284
61. Qu L Jin J Lou J Qian C Lin J Xu A Liu B Zhang M Tao H Yu W The nuclear transportation of PD-L1 and the function in tumor immunity and progression Cancer Immunol Immunother 2022 71 2313 23 10.1007/s00262-022-03176-7 35246703
Qu L, Jin J, Lou J, Qian C, Lin J, Xu A, Liu B, Zhang M, Tao H, Yu W. The nuclear transportation of PD-L1 and the function in tumor immunity and progression. Cancer Immunol Immunother. 2022;71:2313–23.35246703 10.1007/s00262-022-03176-7
62. Yamaguchi H Hsu JM Yang WH Hung MC Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics Nat Rev Clin Oncol 2022 19 287 305 10.1038/s41571-022-00601-9 35132224
Yamaguchi H, Hsu JM, Yang WH, Hung MC. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat Rev Clin Oncol. 2022;19:287–305.35132224 10.1038/s41571-022-00601-9
63. Hu X Lin Z Wang Z Zhou Q Emerging role of PD-L1 modification in cancer immunotherapy Am J Cancer Res 2021 11 3832 40 34522452
Hu X, Lin Z, Wang Z, Zhou Q. Emerging role of PD-L1 modification in cancer immunotherapy. Am J Cancer Res. 2021;11:3832–40.34522452
64. Schafer VS Brossart P Warrington KJ Kurts C Sendtner GW Aden CA The role of autoimmunity and autoinflammation in giant cell arteritis: a systematic literature review Autoimmun Rev 2023 22 103328 10.1016/j.autrev.2023.103328 36990133
Schafer VS, Brossart P, Warrington KJ, Kurts C, Sendtner GW, Aden CA. The role of autoimmunity and autoinflammation in giant cell arteritis: a systematic literature review. Autoimmun Rev. 2023;22:103328.36990133 10.1016/j.autrev.2023.103328
65. Ashrafizadeh M Zarrabi A Hushmandi K Zarrin V Moghadam ER Zabolian A Tavakol S Samarghandian S Najafi M PD-1/PD-L1 axis regulation in cancer therapy: the role of long non-coding RNAs and microRNAs Life Sci 2020 256 117899 10.1016/j.lfs.2020.117899 32504749
Ashrafizadeh M, Zarrabi A, Hushmandi K, Zarrin V, Moghadam ER, Zabolian A, Tavakol S, Samarghandian S, Najafi M. PD-1/PD-L1 axis regulation in cancer therapy: the role of long non-coding RNAs and microRNAs. Life Sci. 2020;256:117899.32504749 10.1016/j.lfs.2020.117899
66. Liu J Wu M Yang Y Wang Z He S Tian X Wang H Gammadelta T cells and the PD-1/PD-L1 axis: a love-hate relationship in the tumor microenvironment J Transl Med 2024 22 553 10.1186/s12967-024-05327-z 38858763
Liu J, Wu M, Yang Y, Wang Z, He S, Tian X, Wang H. Gammadelta T cells and the PD-1/PD-L1 axis: a love-hate relationship in the tumor microenvironment. J Transl Med. 2024;22:553.38858763 10.1186/s12967-024-05327-z
67. Khosravi GR Mostafavi S Bastan S Ebrahimi N Gharibvand RS Eskandari N Immunologic tumor microenvironment modulators for turning cold tumors hot Cancer Commun (Lond) 2024 44 521 53 10.1002/cac2.12539 38551889
Khosravi GR, Mostafavi S, Bastan S, Ebrahimi N, Gharibvand RS, Eskandari N. Immunologic tumor microenvironment modulators for turning cold tumors hot. Cancer Commun (Lond). 2024;44:521–53.38551889 10.1002/cac2.12539
68. Zhang J Fan J Zeng X Nie M Luan J Wang Y Ju D Yin K Hedgehog signaling in gastrointestinal carcinogenesis and the gastrointestinal tumor microenvironment Acta Pharm Sin B 2021 11 609 20 10.1016/j.apsb.2020.10.022 33777671
Zhang J, Fan J, Zeng X, Nie M, Luan J, Wang Y, Ju D, Yin K. Hedgehog signaling in gastrointestinal carcinogenesis and the gastrointestinal tumor microenvironment. Acta Pharm Sin B. 2021;11:609–20.33777671 10.1016/j.apsb.2020.10.022
69. Ji Z Shen J Lan Y Yi Q Liu H Targeting signaling pathways in osteosarcoma: mechanisms and clinical studies MedComm 2020 4 2023 e308
Ji Z, Shen J, Lan Y, Yi Q, Liu H. Targeting signaling pathways in osteosarcoma: mechanisms and clinical studies. MedComm. 2020;4(2023):e308.
70. Li C Cai C Xu D Chen X Song J Activation, signaling, cancer and therapy Pharmacol Res 2024 TREM1 107212 10.1016/j.phrs.2024.107212
Li C, Cai C, Xu D, Chen X, Song J. Activation, signaling, cancer and therapy. Pharmacol Res. 2024;TREM1:107212.10.1016/j.phrs.2024.107212
71. He R Huang S Lu J Su L Gao X Chi H Unveiling the immune symphony: decoding colorectal cancer metastasis through immune interactions Front Immunol 2024 15 1362709 10.3389/fimmu.2024.1362709 38415252
He R, Huang S, Lu J, Su L, Gao X, Chi H. Unveiling the immune symphony: decoding colorectal cancer metastasis through immune interactions. Front Immunol. 2024;15:1362709.38415252 10.3389/fimmu.2024.1362709
72. Yao P Liang S Liu Z Xu C A review of natural products targeting tumor immune microenvironments for the treatment of lung cancer Front Immunol 2024 15 1343316 10.3389/fimmu.2024.1343316 38361933
Yao P, Liang S, Liu Z, Xu C. A review of natural products targeting tumor immune microenvironments for the treatment of lung cancer. Front Immunol. 2024;15:1343316.38361933 10.3389/fimmu.2024.1343316
73. He Y, Zhu M, Lai X, Zhang H, Jiang W. The roles of PD-L1 in the various stages of tumor metastasis. Cancer Metastasis Rev, (2024).
74. Lu MM Yang Y Exosomal PD-L1 in cancer and other fields: recent advances and perspectives Front Immunol 2024 15 1395332 10.3389/fimmu.2024.1395332 38726017
Lu MM, Yang Y. Exosomal PD-L1 in cancer and other fields: recent advances and perspectives. Front Immunol. 2024;15:1395332.38726017 10.3389/fimmu.2024.1395332
75. Fan Z Wu C Chen M Jiang Y Wu Y Mao R Fan Y The generation of PD-L1 and PD-L2 in cancer cells: from nuclear chromatin reorganization to extracellular presentation Acta Pharm Sin B 2022 12 1041 53 10.1016/j.apsb.2021.09.010 35530130
Fan Z, Wu C, Chen M, Jiang Y, Wu Y, Mao R, Fan Y. The generation of PD-L1 and PD-L2 in cancer cells: from nuclear chromatin reorganization to extracellular presentation. Acta Pharm Sin B. 2022;12:1041–53.35530130 10.1016/j.apsb.2021.09.010
76. Bailly C Regulation of PD-L1 expression on cancer cells with ROS-modulating drugs Life Sci 2020 246 117403 10.1016/j.lfs.2020.117403 32035131
Bailly C. Regulation of PD-L1 expression on cancer cells with ROS-modulating drugs. Life Sci. 2020;246:117403.32035131 10.1016/j.lfs.2020.117403
77. Yang M Cui M Sun Y Liu S Jiang W Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance Cell Commun Signal 2024 22 338 10.1186/s12964-024-01711-w 38898505
Yang M, Cui M, Sun Y, Liu S, Jiang W. Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance. Cell Commun Signal. 2024;22:338.38898505 10.1186/s12964-024-01711-w
78. Wang Z Zhang J An F Zhang J Meng X Liu S Xia R Wang G Yan C The mechanism of dendritic cell-T cell crosstalk in rheumatoid arthritis Arthritis Res Ther 2023 25 193 10.1186/s13075-023-03159-8 37798668
Wang Z, Zhang J, An F, Zhang J, Meng X, Liu S, Xia R, Wang G, Yan C. The mechanism of dendritic cell-T cell crosstalk in rheumatoid arthritis. Arthritis Res Ther. 2023;25:193.37798668 10.1186/s13075-023-03159-8
79. Vaseq R, Sharma A, Li Y, Schmidt-Wolf IGH. Revising the Landscape of Cytokine-Induced Killer Cell Therapy in Lung Cancer: Focus on Immune Checkpoint inhibitors. Int J Mol Sci, 24 (2023).
80. Tang W Chen J Ji T Cong X TIGIT, a novel immune checkpoint therapy for melanoma Cell Death Dis 2023 14 466 10.1038/s41419-023-05961-3 37495610
Tang W, Chen J, Ji T, Cong X. TIGIT, a novel immune checkpoint therapy for melanoma. Cell Death Dis. 2023;14:466.37495610 10.1038/s41419-023-05961-3
81. Dong S Guo X Han F He Z Wang Y Emerging role of natural products in cancer immunotherapy Acta Pharm Sin B 2022 12 1163 85 10.1016/j.apsb.2021.08.020 35530162
Dong S, Guo X, Han F, He Z, Wang Y. Emerging role of natural products in cancer immunotherapy. Acta Pharm Sin B. 2022;12:1163–85.35530162 10.1016/j.apsb.2021.08.020
82. Qiu J, Cheng Z, Jiang Z, Gan L, Zhang Z, Xie Z. Immunomodulatory Precision: a narrative review exploring the critical role of Immune checkpoint inhibitors in Cancer Treatment. Int J Mol Sci, 25 (2024).
83. Adeniran AJ Shuch B Humphrey PA Sarcomatoid and Rhabdoid Renal Cell Carcinoma: clinical, pathologic, and Molecular Genetic features Am J Surg Pathol 2024 48 e65 88 10.1097/PAS.0000000000002233 38736105
Adeniran AJ, Shuch B, Humphrey PA. Sarcomatoid and Rhabdoid Renal Cell Carcinoma: clinical, pathologic, and Molecular Genetic features. Am J Surg Pathol. 2024;48:e65–88.38736105 10.1097/PAS.0000000000002233
84. Merhi M Ahmad F Taib N Inchakalody V Uddin S Shablak A Dermime S The complex network of transcription factors, immune checkpoint inhibitors and stemness features in colorectal cancer: a recent update Semin Cancer Biol 2023 89 1 17 10.1016/j.semcancer.2023.01.001 36621515
Merhi M, Ahmad F, Taib N, Inchakalody V, Uddin S, Shablak A, Dermime S. The complex network of transcription factors, immune checkpoint inhibitors and stemness features in colorectal cancer: a recent update. Semin Cancer Biol. 2023;89:1–17.36621515 10.1016/j.semcancer.2023.01.001
85. Kreidieh FY Tawbi HA The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition Ther Adv Med Oncol 2023 15 17588359231186027 10.1177/17588359231186027 37484526
Kreidieh FY, Tawbi HA. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition. Ther Adv Med Oncol. 2023;15:17588359231186027.37484526 10.1177/17588359231186027
86. Chavanton A, Mialhe F, Abrey J, Baeza Garcia A, Garrido C. LAG-3: recent developments in combinational therapies in cancer. Cancer Sci, (2024).
87. Zabeti Touchaei A Vahidi S MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways Cancer Cell Int 2024 24 102 10.1186/s12935-024-03293-6 38462628
Zabeti Touchaei A, Vahidi S. MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways. Cancer Cell Int. 2024;24:102.38462628 10.1186/s12935-024-03293-6
88. Burke KP Chaudhri A Freeman GJ Sharpe AH The B7:CD28 family and friends: unraveling coinhibitory interactions Immunity 2024 57 223 44 10.1016/j.immuni.2024.01.013 38354702
Burke KP, Chaudhri A, Freeman GJ, Sharpe AH. The B7:CD28 family and friends: unraveling coinhibitory interactions. Immunity. 2024;57:223–44.38354702 10.1016/j.immuni.2024.01.013
89. Zhou X Zou L Liao H Luo J Yang T Wu J Chen W Wu K Cen S Lv D Shu F Yang Y Li C Li B Mao X Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8(+) T cell-mediated ferroptosis in castration-resistant prostate cancer Acta Pharm Sin B 2022 12 692 707 10.1016/j.apsb.2021.07.016 35256940
Zhou X, Zou L, Liao H, Luo J, Yang T, Wu J, Chen W, Wu K, Cen S, Lv D, Shu F, Yang Y, Li C, Li B, Mao X. Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8(+) T cell-mediated ferroptosis in castration-resistant prostate cancer. Acta Pharm Sin B. 2022;12:692–707.35256940 10.1016/j.apsb.2021.07.016
90. Jin X, Ding D, Yan Y, Li H, Wang B, Ma L, Ye Z, Ma T, Wu Q, Rodrigues DN, Kohli M, Jimenez R, Wang L, Goodrich DW, de Bono J, Dong H, Wu H, Zhu R, Huang H. Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-kappaB Activation and PD-L1 Expression, Mol Cell, 73 (2019) 22–35 e26.
91. Wang L Xu T Yang X Liang Z Zhang J Li D Chen Y Ma G Wang Y Liang Y Niu H Immunosuppression Induced by glutamine deprivation occurs via activating PD-L1 transcription in bladder Cancer Front Mol Biosci 2021 8 687305 10.3389/fmolb.2021.687305 34805266
Wang L, Xu T, Yang X, Liang Z, Zhang J, Li D, Chen Y, Ma G, Wang Y, Liang Y, Niu H. Immunosuppression Induced by glutamine deprivation occurs via activating PD-L1 transcription in bladder Cancer. Front Mol Biosci. 2021;8:687305.34805266 10.3389/fmolb.2021.687305
92. Lv J Wu Q Li K Bai K Yu H Zhuang J Sun H Yang H Yang X Lu Q Lysine N-methyltransferase SETD7 promotes bladder cancer progression and immune escape via STAT3/PD-L1 cascade Int J Biol Sci 2023 19 3744 61 10.7150/ijbs.87182 37564199
Lv J, Wu Q, Li K, Bai K, Yu H, Zhuang J, Sun H, Yang H, Yang X, Lu Q. Lysine N-methyltransferase SETD7 promotes bladder cancer progression and immune escape via STAT3/PD-L1 cascade. Int J Biol Sci. 2023;19:3744–61.37564199 10.7150/ijbs.87182
93. Zhang C Duan Y Xia M Dong Y Chen Y Zheng L Chai S Zhang Q Wei Z Liu N Wang J Sun C Tang Z Cheng X Wu J Wang G Zheng F Laurence A Li B Yang XP TFEB mediates Immune Evasion and Resistance to mTOR inhibition of renal cell carcinoma via induction of PD-L1 Clin Cancer Res 2019 25 6827 38 10.1158/1078-0432.CCR-19-0733 31383732
Zhang C, Duan Y, Xia M, Dong Y, Chen Y, Zheng L, Chai S, Zhang Q, Wei Z, Liu N, Wang J, Sun C, Tang Z, Cheng X, Wu J, Wang G, Zheng F, Laurence A, Li B, Yang XP. TFEB mediates Immune Evasion and Resistance to mTOR inhibition of renal cell carcinoma via induction of PD-L1. Clin Cancer Res. 2019;25:6827–38.31383732 10.1158/1078-0432.CCR-19-0733
94. Guo X Li R Bai Q Jiang S Wang H TFE3-PD-L1 axis is pivotal for sunitinib resistance in clear cell renal cell carcinoma J Cell Mol Med 2020 24 14441 52 10.1111/jcmm.16066 33145941
Guo X, Li R, Bai Q, Jiang S, Wang H. TFE3-PD-L1 axis is pivotal for sunitinib resistance in clear cell renal cell carcinoma. J Cell Mol Med. 2020;24:14441–52.33145941 10.1111/jcmm.16066
95. Kong SK Kim BS Lim H Kim HJ Kim YS Dissection of PD-L1 promoter reveals differential transcriptional regulation of PD-L1 in VHL mutant clear cell renal cell carcinoma Lab Invest 2022 102 352 62 10.1038/s41374-021-00703-5 34789838
Kong SK, Kim BS, Lim H, Kim HJ, Kim YS. Dissection of PD-L1 promoter reveals differential transcriptional regulation of PD-L1 in VHL mutant clear cell renal cell carcinoma. Lab Invest. 2022;102:352–62.34789838 10.1038/s41374-021-00703-5
96. Hsu JM Li CW Lai YJ Hung MC Posttranslational modifications of PD-L1 and their applications in Cancer Therapy Cancer Res 2018 78 6349 53 10.1158/0008-5472.CAN-18-1892 30442814
Hsu JM, Li CW, Lai YJ, Hung MC. Posttranslational modifications of PD-L1 and their applications in Cancer Therapy. Cancer Res. 2018;78:6349–53.30442814 10.1158/0008-5472.CAN-18-1892
97. Zheng R Gao F Mao Z Xiao Y Yuan L Huang Z Lv Q Qin C Du M Zhang Z Wang M LncRNA BCCE4 genetically enhances the PD-L1/PD-1 Interaction in Smoking-related bladder Cancer by modulating mir-328-3p-USP18 signaling Adv Sci (Weinh) 2023 10 e2303473 10.1002/advs.202303473 37705121
Zheng R, Gao F, Mao Z, Xiao Y, Yuan L, Huang Z, Lv Q, Qin C, Du M, Zhang Z, Wang M. LncRNA BCCE4 genetically enhances the PD-L1/PD-1 Interaction in Smoking-related bladder Cancer by modulating mir-328-3p-USP18 signaling. Adv Sci (Weinh). 2023;10:e2303473.37705121 10.1002/advs.202303473
98. Ni Z Sun P Zheng J Wu M Yang C Cheng M Yin M Cui C Wang G Yuan L Gao Q Li Y JNK Signaling promotes bladder Cancer Immune escape by regulating METTL3-Mediated m6A modification of PD-L1 mRNA Cancer Res 2022 82 1789 802 10.1158/0008-5472.CAN-21-1323 35502544
Ni Z, Sun P, Zheng J, Wu M, Yang C, Cheng M, Yin M, Cui C, Wang G, Yuan L, Gao Q, Li Y. JNK Signaling promotes bladder Cancer Immune escape by regulating METTL3-Mediated m6A modification of PD-L1 mRNA. Cancer Res. 2022;82:1789–802.35502544 10.1158/0008-5472.CAN-21-1323
99. Jing W Wang G Cui Z Xiong G Jiang X Li Y Li W Han B Chen S Shi B FGFR3 destabilizes PD-L1 via NEDD4 to control T-cell-mediated bladder Cancer Immune Surveillance Cancer Res 2022 82 114 29 10.1158/0008-5472.CAN-21-2362 34753771
Jing W, Wang G, Cui Z, Xiong G, Jiang X, Li Y, Li W, Han B, Chen S, Shi B. FGFR3 destabilizes PD-L1 via NEDD4 to control T-cell-mediated bladder Cancer Immune Surveillance. Cancer Res. 2022;82:114–29.34753771 10.1158/0008-5472.CAN-21-2362
100. Ho SR Lee YC Ittmann MM Lin FT Chan KS Lin WC RNF144A deficiency promotes PD-L1 protein stabilization and carcinogen-induced bladder tumorigenesis Cancer Lett 2021 520 344 60 10.1016/j.canlet.2021.08.008 34400221
Ho SR, Lee YC, Ittmann MM, Lin FT, Chan KS, Lin WC. RNF144A deficiency promotes PD-L1 protein stabilization and carcinogen-induced bladder tumorigenesis. Cancer Lett. 2021;520:344–60.34400221 10.1016/j.canlet.2021.08.008
101. Wu P Geng B Chen Q Zhao E Liu J Sun C Zha C Shao Y You B Zhang W Li L Meng X Cai J Li X Tumor Cell-Derived TGFbeta1 attenuates Antitumor Immune activity of T cells via regulation of PD-1 mRNA Cancer Immunol Res 2020 8 1470 84 10.1158/2326-6066.CIR-20-0113 32999004
Wu P, Geng B, Chen Q, Zhao E, Liu J, Sun C, Zha C, Shao Y, You B, Zhang W, Li L, Meng X, Cai J, Li X. Tumor Cell-Derived TGFbeta1 attenuates Antitumor Immune activity of T cells via regulation of PD-1 mRNA. Cancer Immunol Res. 2020;8:1470–84.32999004 10.1158/2326-6066.CIR-20-0113
102. Qin Z, Hu H, Sun W, Chen L, Jin S, Xu Q, Liu Y, Yu L, Zeng S. Mir-224-5p contained in urinary extracellular vesicles regulates PD-L1 expression by inhibiting cyclin D1 in renal cell carcinoma cells. Cancers (Basel), 13 (2021).
103. Weber EW Maus MV Mackall CL Emerg Landsc Immune Cell Ther Cell 2020 181 46 62
Weber EW, Maus MV, Mackall CL. Emerg Landsc Immune Cell Ther Cell. 2020;181:46–62.
104. Sun C Mezzadra R Schumacher TN Regulation and function of the PD-L1 checkpoint Immunity 2018 48 434 52 10.1016/j.immuni.2018.03.014 29562194
Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48:434–52.29562194 10.1016/j.immuni.2018.03.014
105. Feng C Zhang L Chang X Qin D Zhang T Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy Front Immunol 2023 14 1230135 10.3389/fimmu.2023.1230135 37554324
Feng C, Zhang L, Chang X, Qin D, Zhang T. Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy. Front Immunol. 2023;14:1230135.37554324 10.3389/fimmu.2023.1230135
106. Carosella ED Ploussard G LeMaoult J Desgrandchamps F Review of Immunotherapy in Urologic Cancer: evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G Eur Urol 2015 68 267 79 10.1016/j.eururo.2015.02.032 25824720
Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F. Review of Immunotherapy in Urologic Cancer: evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol. 2015;68:267–79.25824720 10.1016/j.eururo.2015.02.032
107. Morel KL Sheahan AV Burkhart DL Baca SC Boufaied N Liu Y Qiu X Canadas I Roehle K Heckler M Calagua C Ye H Pantelidou C Galbo P Panja S Mitrofanova A Wilkinson S Whitlock NC Trostel SY Hamid AA Kibel AS Barbie DA Choudhury AD Pomerantz MM Sweeney CJ Long HW Einstein DJ Shapiro GI Dougan SK Sowalsky AG He HH Freedman ML Balk SP Loda M Labbe DP Olson BM Ellis L EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer Nat Cancer 2021 2 444 56 10.1038/s43018-021-00185-w 33899001
Morel KL, Sheahan AV, Burkhart DL, Baca SC, Boufaied N, Liu Y, Qiu X, Canadas I, Roehle K, Heckler M, Calagua C, Ye H, Pantelidou C, Galbo P, Panja S, Mitrofanova A, Wilkinson S, Whitlock NC, Trostel SY, Hamid AA, Kibel AS, Barbie DA, Choudhury AD, Pomerantz MM, Sweeney CJ, Long HW, Einstein DJ, Shapiro GI, Dougan SK, Sowalsky AG, He HH, Freedman ML, Balk SP, Loda M, Labbe DP, Olson BM, Ellis L. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021;2:444–56.33899001 10.1038/s43018-021-00185-w
108. Zhang Y Wei Y Jiang S Dang Y Yang Y Zuo W Zhu Q Liu P Gao Y Lu S Traditional Chinese medicine CFF-1 exerts a potent anti-tumor immunity to hinder tumor growth and metastasis in prostate cancer through EGFR/JAK1/STAT3 pathway to inhibit PD-1/PD-L1 checkpoint signaling Phytomedicine 2022 99 153939 10.1016/j.phymed.2022.153939 35172257
Zhang Y, Wei Y, Jiang S, Dang Y, Yang Y, Zuo W, Zhu Q, Liu P, Gao Y, Lu S. Traditional Chinese medicine CFF-1 exerts a potent anti-tumor immunity to hinder tumor growth and metastasis in prostate cancer through EGFR/JAK1/STAT3 pathway to inhibit PD-1/PD-L1 checkpoint signaling. Phytomedicine. 2022;99:153939.35172257 10.1016/j.phymed.2022.153939
109. Wang M Wisniewski CA Xiong C Chhoy P Goel HL Kumar A Zhu LJ Li R St Louis PA Ferreira LM Pakula H Xu Z Loda M Jiang Z Brehm MA Mercurio AM Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer Sci Transl Med 2023 15 eade5855 10.1126/scitranslmed.ade5855 37134151
Wang M, Wisniewski CA, Xiong C, Chhoy P, Goel HL, Kumar A, Zhu LJ, Li R, St Louis PA, Ferreira LM, Pakula H, Xu Z, Loda M, Jiang Z, Brehm MA, Mercurio AM. Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer. Sci Transl Med. 2023;15:eade5855.37134151 10.1126/scitranslmed.ade5855
110. Yu Y Liang Y Xie F Zhang Z Zhang P Zhao X Zhang Z Liang Z Li D Wang L Chen Y Sun L Niu H Wang Y Tumor-associated macrophage enhances PD-L1-mediated immune escape of bladder cancer through PKM2 dimer-STAT3 complex nuclear translocation Cancer Lett 2024 593 216964 10.1016/j.canlet.2024.216964 38762193
Yu Y, Liang Y, Xie F, Zhang Z, Zhang P, Zhao X, Zhang Z, Liang Z, Li D, Wang L, Chen Y, Sun L, Niu H, Wang Y. Tumor-associated macrophage enhances PD-L1-mediated immune escape of bladder cancer through PKM2 dimer-STAT3 complex nuclear translocation. Cancer Lett. 2024;593:216964.38762193 10.1016/j.canlet.2024.216964
111. Liu W Ren D Xiong W Jin X Zhu L A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression J Exp Clin Cancer Res 2022 41 38 10.1186/s13046-022-02253-0 35081978
Liu W, Ren D, Xiong W, Jin X, Zhu L. A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression. J Exp Clin Cancer Res. 2022;41:38.35081978 10.1186/s13046-022-02253-0
112. Hanze J Wegner M Noessner E Hofmann R Hegele A Co-regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling Is Associated with a Survival Benefit in Renal Cell Cancer Target Oncol 2020 15 377 90 10.1007/s11523-020-00728-8 32495158
Hanze J, Wegner M, Noessner E, Hofmann R, Hegele A. Co-regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling Is Associated with a Survival Benefit in Renal Cell Cancer. Target Oncol. 2020;15:377–90.32495158 10.1007/s11523-020-00728-8
113. Li L Zhang Y Hu W Zou F Ning J Rao T Ruan Y Yu W Cheng F MTHFD2 promotes PD-L1 expression via activation of the JAK/STAT signalling pathway in bladder cancer J Cell Mol Med 2023 27 2922 36 10.1111/jcmm.17863 37480214
Li L, Zhang Y, Hu W, Zou F, Ning J, Rao T, Ruan Y, Yu W, Cheng F. MTHFD2 promotes PD-L1 expression via activation of the JAK/STAT signalling pathway in bladder cancer. J Cell Mol Med. 2023;27:2922–36.37480214 10.1111/jcmm.17863
114. Kim Y Lin Q Glazer PM Yun Z Hypoxic tumor microenvironment and cancer cell differentiation Curr Mol Med 2009 9 425 34 10.2174/156652409788167113 19519400
Kim Y, Lin Q, Glazer PM, Yun Z. Hypoxic tumor microenvironment and cancer cell differentiation. Curr Mol Med. 2009;9:425–34.19519400 10.2174/156652409788167113
115. Hirschhaeuser F Sattler UG Mueller-Klieser W Lactate: a metabolic key player in cancer Cancer Res 2011 71 6921 5 10.1158/0008-5472.CAN-11-1457 22084445
Hirschhaeuser F, Sattler UG, Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res. 2011;71:6921–5.22084445 10.1158/0008-5472.CAN-11-1457
116. Yu Y Liang Y Li D Wang L Liang Z Chen Y Ma G Wu H Jiao W Niu H Glucose metabolism involved in PD-L1-mediated immune escape in the malignant kidney tumour microenvironment Cell Death Discov 2021 7 15 10.1038/s41420-021-00401-7 33462221
Yu Y, Liang Y, Li D, Wang L, Liang Z, Chen Y, Ma G, Wu H, Jiao W, Niu H. Glucose metabolism involved in PD-L1-mediated immune escape in the malignant kidney tumour microenvironment. Cell Death Discov. 2021;7:15.33462221 10.1038/s41420-021-00401-7
117. Li J, Sun H, Fu M, Zheng Z, Xu C, Yang K, Liu Y, Xuan Z, Bai Y, Zheng J, Zhao Y, Shi Z, Shao C. TOPK mediates immune evasion of renal cell carcinoma via upregulating the expression of PD-L1, iScience, 26 (2023) 107185.
118. Reid MA Wang WI Rosales KR Welliver MX Pan M Kong M The B55alpha subunit of PP2A drives a p53-dependent metabolic adaptation to glutamine deprivation Mol Cell 2013 50 200 11 10.1016/j.molcel.2013.02.008 23499005
Reid MA, Wang WI, Rosales KR, Welliver MX, Pan M, Kong M. The B55alpha subunit of PP2A drives a p53-dependent metabolic adaptation to glutamine deprivation. Mol Cell. 2013;50:200–11.23499005 10.1016/j.molcel.2013.02.008
119. Ma G Liang Y Chen Y Wang L Li D Liang Z Wang X Tian D Yang X Niu H Glutamine deprivation induces PD-L1 expression via activation of EGFR/ERK/c-Jun Signaling in Renal Cancer Mol Cancer Res 2020 18 324 39 10.1158/1541-7786.MCR-19-0517 31672701
Ma G, Liang Y, Chen Y, Wang L, Li D, Liang Z, Wang X, Tian D, Yang X, Niu H. Glutamine deprivation induces PD-L1 expression via activation of EGFR/ERK/c-Jun Signaling in Renal Cancer. Mol Cancer Res. 2020;18:324–39.31672701 10.1158/1541-7786.MCR-19-0517
120. Deng X, Liu X, Hu B, Liu J, Fu B, Zhang W. Upregulation of MTHFD2 is associated with PD–L1 activation in bladder cancer via the PI3K/AKT pathway. Int J Mol Med, 51 (2023).
121. Lee HJ Shin DH Song JS Park JY Kim SY Hwang CS Na JY Lee JH Kim JY Park SW Sol MY mTOR inhibition increases transcription factor E3 (TFE3) activity and modulates programmed death-ligand 1 (PD-L1) expression in translocation renal cell carcinoma Am J Pathol 2021 191 1999 2008 10.1016/j.ajpath.2021.07.007 34358517
Lee HJ, Shin DH, Song JS, Park JY, Kim SY, Hwang CS, Na JY, Lee JH, Kim JY, Park SW, Sol MY. mTOR inhibition increases transcription factor E3 (TFE3) activity and modulates programmed death-ligand 1 (PD-L1) expression in translocation renal cell carcinoma. Am J Pathol. 2021;191:1999–2008.34358517 10.1016/j.ajpath.2021.07.007
122. Liu Q You B Meng J Huang CP Dong G Wang R Chou F Gao S Chang C Yeh S Xu W Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling Cancer Gene Ther 2022 29 1988 2000 10.1038/s41417-022-00506-w 35915245
Liu Q, You B, Meng J, Huang CP, Dong G, Wang R, Chou F, Gao S, Chang C, Yeh S, Xu W. Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling. Cancer Gene Ther. 2022;29:1988–2000.35915245 10.1038/s41417-022-00506-w
123. Chen KC Dhar T Chen CR Chen EC Peng CC Nicotinamide phosphoribosyltransferase modulates PD-L1 in bladder cancer and enhances immunotherapeutic sensitivity Biochim Biophys Acta Mol Basis Dis 2024 1870 167106 10.1016/j.bbadis.2024.167106 38428685
Chen KC, Dhar T, Chen CR, Chen EC, Peng CC. Nicotinamide phosphoribosyltransferase modulates PD-L1 in bladder cancer and enhances immunotherapeutic sensitivity. Biochim Biophys Acta Mol Basis Dis. 2024;1870:167106.38428685 10.1016/j.bbadis.2024.167106
124. Xiong W Zhang B Yu H Zhu L Yi L Jin X RRM2 regulates sensitivity to Sunitinib and PD-1 blockade in Renal Cancer by stabilizing ANXA1 and activating the AKT pathway Adv Sci (Weinh) 2021 8 e2100881 10.1002/advs.202100881 34319001
Xiong W, Zhang B, Yu H, Zhu L, Yi L, Jin X. RRM2 regulates sensitivity to Sunitinib and PD-1 blockade in Renal Cancer by stabilizing ANXA1 and activating the AKT pathway. Adv Sci (Weinh). 2021;8:e2100881.34319001 10.1002/advs.202100881
125. Huang S Liu J Hu J Hou Y Hu M Zhang B Luo H Fu S Chen Y Liu X Chen Z Wang L GHITM regulates malignant phenotype and sensitivity to PD-1 blockade of renal cancer cells via notch signalling J Cell Mol Med 2024 28 e18290 10.1111/jcmm.18290 38588015
Huang S, Liu J, Hu J, Hou Y, Hu M, Zhang B, Luo H, Fu S, Chen Y, Liu X, Chen Z, Wang L. GHITM regulates malignant phenotype and sensitivity to PD-1 blockade of renal cancer cells via notch signalling. J Cell Mol Med. 2024;28:e18290.38588015 10.1111/jcmm.18290
126. Topalian SL Drake CG Pardoll DM Immune checkpoint blockade: a common denominator approach to cancer therapy Cancer Cell 2015 27 450 61 10.1016/j.ccell.2015.03.001 25858804
Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–61.25858804 10.1016/j.ccell.2015.03.001
127. Kruger S Ilmer M Kobold S Cadilha BL Endres S Ormanns S Schuebbe G Renz BW D’Haese JG Schloesser H Heinemann V Subklewe M Boeck S von Werner J Bergwelt-Baildon, advances in cancer immunotherapy 2019 - latest trends J Exp Clin Cancer Res 2019 38 268 10.1186/s13046-019-1266-0 31217020
Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebbe G, Renz BW, D’Haese JG, Schloesser H, Heinemann V, Subklewe M, Boeck S, von Werner J. Bergwelt-Baildon, advances in cancer immunotherapy 2019 - latest trends. J Exp Clin Cancer Res. 2019;38:268.31217020 10.1186/s13046-019-1266-0
128. Jiang Y Chen M Nie H Yuan Y PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations Hum Vaccin Immunother 2019 15 1111 22 10.1080/21645515.2019.1571892 30888929
Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019;15:1111–22.30888929 10.1080/21645515.2019.1571892
129. Zahm CD Moseman JE Delmastro LE D GM PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy Oncoimmunology 2021 10 1912892 10.1080/2162402X.2021.1912892 33996265
Zahm CD, Moseman JE, Delmastro LE, D GM. PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy. Oncoimmunology. 2021;10:1912892.33996265 10.1080/2162402X.2021.1912892
130. Zhang X Chen H Li G Zhou X Shi Y Zou F Chen Y Gao J Yang S Wu S Long Z Increased Tim-3 expression on TILs during treatment with the anchored GM-CSF vaccine and anti-PD-1 antibodies is inversely correlated with response in prostate cancer J Cancer 2020 11 648 56 10.7150/jca.29705 31942188
Zhang X, Chen H, Li G, Zhou X, Shi Y, Zou F, Chen Y, Gao J, Yang S, Wu S, Long Z. Increased Tim-3 expression on TILs during treatment with the anchored GM-CSF vaccine and anti-PD-1 antibodies is inversely correlated with response in prostate cancer. J Cancer. 2020;11:648–56.31942188 10.7150/jca.29705
131. Chang WL Hsu LC Leu WJ Chen CS Guh JH Repurposing of Nitroxoline as a potential anticancer agent against human prostate cancer: a crucial role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation Oncotarget 2015 6 39806 20 10.18632/oncotarget.5655 26447757
Chang WL, Hsu LC, Leu WJ, Chen CS, Guh JH. Repurposing of Nitroxoline as a potential anticancer agent against human prostate cancer: a crucial role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation. Oncotarget. 2015;6:39806–20.26447757 10.18632/oncotarget.5655
132. Mao H Du Y Zhang Z Cao B Zhao J Zhou H Mao X Nitroxoline shows antimyeloma activity by targeting the TRIM25/p53 axle Anticancer Drugs 2017 28 376 83 10.1097/CAD.0000000000000466 28301380
Mao H, Du Y, Zhang Z, Cao B, Zhao J, Zhou H, Mao X. Nitroxoline shows antimyeloma activity by targeting the TRIM25/p53 axle. Anticancer Drugs. 2017;28:376–83.28301380 10.1097/CAD.0000000000000466
133. Xu N Huang L Li X Watanabe M Li C Xu A Liu C Li Q Araki M Wada K Nasu Y Huang P The Novel combination of Nitroxoline and PD-1 blockade, exerts a potent Antitumor Effect in a mouse model of prostate Cancer Int J Biol Sci 2019 15 919 28 10.7150/ijbs.32259 31182913
Xu N, Huang L, Li X, Watanabe M, Li C, Xu A, Liu C, Li Q, Araki M, Wada K, Nasu Y, Huang P. The Novel combination of Nitroxoline and PD-1 blockade, exerts a potent Antitumor Effect in a mouse model of prostate Cancer. Int J Biol Sci. 2019;15:919–28.31182913 10.7150/ijbs.32259
134. Kunimura N Kitagawa K Sako R Narikiyo K Tominaga S Bautista DS Xu W Fujisawa M Shirakawa T Combination of rAd-p53 in situ gene therapy and anti-PD-1 antibody immunotherapy induced anti-tumor activity in mouse syngeneic urogenital cancer models Sci Rep 2020 10 17464 10.1038/s41598-020-74660-2 33060772
Kunimura N, Kitagawa K, Sako R, Narikiyo K, Tominaga S, Bautista DS, Xu W, Fujisawa M, Shirakawa T. Combination of rAd-p53 in situ gene therapy and anti-PD-1 antibody immunotherapy induced anti-tumor activity in mouse syngeneic urogenital cancer models. Sci Rep. 2020;10:17464.33060772 10.1038/s41598-020-74660-2
135. Zhou S Wang B Wei Y Dai P Chen Y Xiao Y Xia H Chen C Yin W PD-1 inhibitor combined with Docetaxel exerts synergistic anti-prostate cancer effect in mice by down-regulating the expression of PI3K/AKT/NFKB-P65/PD-L1 signaling pathway Cancer Biomark 2024 40 47 59 10.3233/CBM-230090 38306024
Zhou S, Wang B, Wei Y, Dai P, Chen Y, Xiao Y, Xia H, Chen C, Yin W. PD-1 inhibitor combined with Docetaxel exerts synergistic anti-prostate cancer effect in mice by down-regulating the expression of PI3K/AKT/NFKB-P65/PD-L1 signaling pathway. Cancer Biomark. 2024;40:47–59.38306024 10.3233/CBM-230090
136. Deng G, He J, Huang Q, Li T, Huang Z, Gao S, Xu J, Wang T, Di J. Ibrutinib inhibits BTK Signaling in Tumor-infiltrated B cells and amplifies Antitumor immunity by PD-1 checkpoint blockade for metastatic prostate Cancer. Cancers (Basel), 15 (2023).
137. Han HS Jeong S Kim H Kim HD Kim AR Kwon M Park SH Woo CG Kim HK Lee KH Seo SP Kang HW Kim WT Kim WJ Yun SJ Shin EC TOX-expressing terminally exhausted tumor-infiltrating CD8(+) T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer Cancer Lett 2021 499 137 47 10.1016/j.canlet.2020.11.035 33249194
Han HS, Jeong S, Kim H, Kim HD, Kim AR, Kwon M, Park SH, Woo CG, Kim HK, Lee KH, Seo SP, Kang HW, Kim WT, Kim WJ, Yun SJ, Shin EC. TOX-expressing terminally exhausted tumor-infiltrating CD8(+) T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer. Cancer Lett. 2021;499:137–47.33249194 10.1016/j.canlet.2020.11.035
138. Freshour SL Chen TH Fisk B Shen H Mosior M Skidmore ZL Fronick C Bolzenius JK Griffith OL Arora VK Griffith M Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer iScience 2023 26 107937 10.1016/j.isci.2023.107937 37810214
Freshour SL, Chen TH, Fisk B, Shen H, Mosior M, Skidmore ZL, Fronick C, Bolzenius JK, Griffith OL, Arora VK, Griffith M. Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer. iScience. 2023;26:107937.37810214 10.1016/j.isci.2023.107937
139. Denis M Grasselly C Choffour PA Wierinckx A Mathe D Chettab K Tourette A Talhi N Bourguignon A Birzele F Kress E Jordheim LP Klein C Matera EL Dumontet C Vivo syngeneic tumor models with Acquired Resistance to Anti-PD-1/PD-L1 therapies Cancer Immunol Res 2022 10 1013 27 10.1158/2326-6066.CIR-21-0802 35679518
Denis M, Grasselly C, Choffour PA, Wierinckx A, Mathe D, Chettab K, Tourette A, Talhi N, Bourguignon A, Birzele F, Kress E, Jordheim LP, Klein C, Matera EL, Dumontet C. Vivo syngeneic tumor models with Acquired Resistance to Anti-PD-1/PD-L1 therapies. Cancer Immunol Res. 2022;10:1013–27.35679518 10.1158/2326-6066.CIR-21-0802
140. Zhao Z Liu S Sun R Zhu W Zhang Y Liu T Li T Jiang N Guo H Yang R The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer Front Immunol 2023 14 1085476 10.3389/fimmu.2023.1085476 36960067
Zhao Z, Liu S, Sun R, Zhu W, Zhang Y, Liu T, Li T, Jiang N, Guo H, Yang R. The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer. Front Immunol. 2023;14:1085476.36960067 10.3389/fimmu.2023.1085476
141. Li H Chen J Li Z Chen M Ou Z Mo M Wang R Tong S Liu P Cai Z Zhang C Liu Z Deng D Liu J Cheng C Hu J Zu X S100A5 attenuates efficiency of Anti-PD-L1/PD-1 immunotherapy by inhibiting CD8(+) T cell-mediated anti-cancer immunity in bladder carcinoma Adv Sci (Weinh) 2023 10 e2300110 10.1002/advs.202300110 37414584
Li H, Chen J, Li Z, Chen M, Ou Z, Mo M, Wang R, Tong S, Liu P, Cai Z, Zhang C, Liu Z, Deng D, Liu J, Cheng C, Hu J, Zu X. S100A5 attenuates efficiency of Anti-PD-L1/PD-1 immunotherapy by inhibiting CD8(+) T cell-mediated anti-cancer immunity in bladder carcinoma. Adv Sci (Weinh). 2023;10:e2300110.37414584 10.1002/advs.202300110
142. Okato A, Utsumi T, Ranieri M, Zheng X, Zhou M, Pereira LD, Chen T, Kita Y, Wu D, Hyun H, Lee H, Gdowski AS, Raupp JD, Clark-Garvey S, Manocha U, Chafitz A, Sherman F, Stephens J, Rose TL, Milowsky MI, Wobker SE, Serody JS, Damrauer JS, Wong KK, Kim WY. FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression. J Clin Invest, 134 (2024).
143. Tsuji S Reil K Nelson K Proclivo VH McGuire KL Giacalone MJ Intravesical VAX014 synergizes with PD-L1 blockade to enhance local and systemic control of bladder Cancer Cancer Immunol Res 2022 10 978 95 10.1158/2326-6066.CIR-21-0879 35679299
Tsuji S, Reil K, Nelson K, Proclivo VH, McGuire KL, Giacalone MJ. Intravesical VAX014 synergizes with PD-L1 blockade to enhance local and systemic control of bladder Cancer. Cancer Immunol Res. 2022;10:978–95.35679299 10.1158/2326-6066.CIR-21-0879
144. Li L Zeng X Chao Z Luo J Guan W Zhang Q Ge Y Wang Y Xiong Z Ma S Zhou Q Zhang J Tian J Horne D Yuh B Hu Z Wei GH Wang B Zhang X Lan P Wang Z Targeting alpha-ketoglutarate disruption overcomes Immunoevasion and improves PD-1 Blockade Immunotherapy in Renal Cell Carcinoma Adv Sci (Weinh) 2023 10 e2301975 10.1002/advs.202301975 37526345
Li L, Zeng X, Chao Z, Luo J, Guan W, Zhang Q, Ge Y, Wang Y, Xiong Z, Ma S, Zhou Q, Zhang J, Tian J, Horne D, Yuh B, Hu Z, Wei GH, Wang B, Zhang X, Lan P, Wang Z. Targeting alpha-ketoglutarate disruption overcomes Immunoevasion and improves PD-1 Blockade Immunotherapy in Renal Cell Carcinoma. Adv Sci (Weinh). 2023;10:e2301975.37526345 10.1002/advs.202301975
145. Adachi Y Kamiyama H Ichikawa K Fukushima S Ozawa Y Yamaguchi S Goda S Kimura T Kodama K Matsuki M Miyano SW Yokoi A Kato Y Funahashi Y Inhibition of FGFR reactivates IFNgamma Signaling in Tumor cells to enhance the combined antitumor activity of Lenvatinib with Anti-PD-1 antibodies Cancer Res 2022 82 292 306 10.1158/0008-5472.CAN-20-2426 34753772
Adachi Y, Kamiyama H, Ichikawa K, Fukushima S, Ozawa Y, Yamaguchi S, Goda S, Kimura T, Kodama K, Matsuki M, Miyano SW, Yokoi A, Kato Y, Funahashi Y. Inhibition of FGFR reactivates IFNgamma Signaling in Tumor cells to enhance the combined antitumor activity of Lenvatinib with Anti-PD-1 antibodies. Cancer Res. 2022;82:292–306.34753772 10.1158/0008-5472.CAN-20-2426
146. Wu FTH Xu P Chow A Man S Kruger J Khan KA Paez-Ribes M Pham E Kerbel RS Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease Br J Cancer 2019 120 196 206 10.1038/s41416-018-0297-1 30498230
Wu FTH, Xu P, Chow A, Man S, Kruger J, Khan KA, Paez-Ribes M, Pham E, Kerbel RS. Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease. Br J Cancer. 2019;120:196–206.30498230 10.1038/s41416-018-0297-1
147. Zelba H Bedke J Hennenlotter J Mostbock S Zettl M Zichner T Chandran A Stenzl A Rammensee HG Gouttefangeas C PD-1 and LAG-3 dominate checkpoint receptor-mediated T-cell inhibition in renal cell carcinoma Cancer Immunol Res 2019 7 1891 9 10.1158/2326-6066.CIR-19-0146 31484656
Zelba H, Bedke J, Hennenlotter J, Mostbock S, Zettl M, Zichner T, Chandran A, Stenzl A, Rammensee HG, Gouttefangeas C. PD-1 and LAG-3 dominate checkpoint receptor-mediated T-cell inhibition in renal cell carcinoma. Cancer Immunol Res. 2019;7:1891–9.31484656 10.1158/2326-6066.CIR-19-0146
148. Orlandella RM, Turbitt WJ, Gibson JT, Boi SK, Li P, Smith DL Jr., Norian LA. The antidiabetic Agent Acarbose improves Anti-PD-1 and rapamycin efficacy in preclinical renal Cancer. Cancers (Basel), 12 (2020).
149. Ferreiro-Pantin M Anido-Herranz U Betancor YZ Cebey-Lopez V Leon-Mateos L Garcia-Gonzalez J Garcia-Acuna SM Fernandez-Diaz N Tubio JMC Lopez-Lopez R Ruiz-Banobre J Clinical, molecular, and immune correlates of the Immunotherapy response score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial ESMO Open 2023 8 101611 10.1016/j.esmoop.2023.101611 37516059
Ferreiro-Pantin M, Anido-Herranz U, Betancor YZ, Cebey-Lopez V, Leon-Mateos L, Garcia-Gonzalez J, Garcia-Acuna SM, Fernandez-Diaz N, Tubio JMC, Lopez-Lopez R, Ruiz-Banobre J. Clinical, molecular, and immune correlates of the Immunotherapy response score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial. ESMO Open. 2023;8:101611.37516059 10.1016/j.esmoop.2023.101611
150. Hopkins AM Kichenadasse G Karapetis CS Rowland A Sorich MJ Concomitant Proton pump inhibitor use and survival in Urothelial Carcinoma Treated with Atezolizumab Clin Cancer Res 2020 26 5487 93 10.1158/1078-0432.CCR-20-1876 32933995
Hopkins AM, Kichenadasse G, Karapetis CS, Rowland A, Sorich MJ. Concomitant Proton pump inhibitor use and survival in Urothelial Carcinoma Treated with Atezolizumab. Clin Cancer Res. 2020;26:5487–93.32933995 10.1158/1078-0432.CCR-20-1876
151. Balar AV Castellano DE Grivas P Vaughn DJ Powles T Vuky J Fradet Y Lee JL Fong L Vogelzang NJ Climent MA Necchi A Petrylak DP Plimack ER Xu JZ Imai K Moreno BH Bellmunt J de Wit R O’Donnell, Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up Ann Oncol 2023 34 289 99 10.1016/j.annonc.2022.11.012 36494006
Balar AV, Castellano DE, Grivas P, Vaughn DJ, Powles T, Vuky J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Necchi A, Petrylak DP, Plimack ER, Xu JZ, Imai K, Moreno BH, Bellmunt J, de Wit R. O’Donnell, Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Ann Oncol. 2023;34:289–99.36494006 10.1016/j.annonc.2022.11.012
152. Bellmunt J de Wit R Fradet Y Climent MA Petrylak DP Lee JL Fong L Necchi A Sternberg CN O’Donnell PH Powles T Plimack ER Bajorin DF Balar AV Castellano D Choueiri TK Culine S Gerritsen W Gurney H Quinn DI Vuky J Vogelzang NJ Cristescu R Lunceford J Saadatpour A Loboda A Ma J Rajasagi M Godwin JL Homet Moreno B Grivas P Putative biomarkers of Clinical Benefit with Pembrolizumab in Advanced Urothelial Cancer: results from the KEYNOTE-045 and KEYNOTE-052 Landmark trials Clin Cancer Res 2022 28 2050 60 10.1158/1078-0432.CCR-21-3089 35247908
Bellmunt J, de Wit R, Fradet Y, Climent MA, Petrylak DP, Lee JL, Fong L, Necchi A, Sternberg CN, O’Donnell PH, Powles T, Plimack ER, Bajorin DF, Balar AV, Castellano D, Choueiri TK, Culine S, Gerritsen W, Gurney H, Quinn DI, Vuky J, Vogelzang NJ, Cristescu R, Lunceford J, Saadatpour A, Loboda A, Ma J, Rajasagi M, Godwin JL, Homet Moreno B, Grivas P. Putative biomarkers of Clinical Benefit with Pembrolizumab in Advanced Urothelial Cancer: results from the KEYNOTE-045 and KEYNOTE-052 Landmark trials. Clin Cancer Res. 2022;28:2050–60.35247908 10.1158/1078-0432.CCR-21-3089
153. Grimm MO Esteban E Barthelemy P Schmidinger M Busch J Valderrama BP Charnley N Schmitz M Schumacher U Leucht K Foller S Baretton G Duran I de Velasco G Priou F Maroto P Albiges L .s. group, tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial Lancet Oncol 2023 24 1252 65 10.1016/S1470-2045(23)00449-7 37844597
Grimm MO, Esteban E, Barthelemy P, Schmidinger M, Busch J, Valderrama BP, Charnley N, Schmitz M, Schumacher U, Leucht K, Foller S, Baretton G, Duran I, de Velasco G, Priou F, Maroto P, Albiges L. .s. group, tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2023;24:1252–65.37844597 10.1016/S1470-2045(23)00449-7
154. Escudier B Motzer RJ Sharma P Wagstaff J Plimack ER Hammers HJ Donskov F Gurney H Sosman JA Zalewski PG Harmenberg U McDermott DF Choueiri TK Richardet M Tomita Y Ravaud A Doan J Zhao H Hardy H George, Treatment Beyond Progression in patients with Advanced Renal Cell Carcinoma treated with Nivolumab in CheckMate 025 Eur Urol 2017 72 368 76 10.1016/j.eururo.2017.03.037 28410865
Escudier B, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, Hammers HJ, Donskov F, Gurney H, Sosman JA, Zalewski PG, Harmenberg U, McDermott DF, Choueiri TK, Richardet M, Tomita Y, Ravaud A, Doan J, Zhao H, Hardy H. George, Treatment Beyond Progression in patients with Advanced Renal Cell Carcinoma treated with Nivolumab in CheckMate 025. Eur Urol. 2017;72:368–76.28410865 10.1016/j.eururo.2017.03.037
155. Albiges L Tannir NM Burotto M McDermott D Plimack ER Barthelemy P Porta C Powles T Donskov F George S Kollmannsberger CK Gurney H Grimm MO Tomita Y Castellano D Rini BI Choueiri TK Leung D Saggi SS Lee CW McHenry MB Motzer RJ First-line Nivolumab plus Ipilimumab Versus Sunitinib in patients without Nephrectomy and with an evaluable primary renal tumor in the CheckMate 214 Trial Eur Urol 2022 81 266 71 10.1016/j.eururo.2021.10.001 34750035
Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthelemy P, Porta C, Powles T, Donskov F, George S, Kollmannsberger CK, Gurney H, Grimm MO, Tomita Y, Castellano D, Rini BI, Choueiri TK, Leung D, Saggi SS, Lee CW, McHenry MB, Motzer RJ. First-line Nivolumab plus Ipilimumab Versus Sunitinib in patients without Nephrectomy and with an evaluable primary renal tumor in the CheckMate 214 Trial. Eur Urol. 2022;81:266–71.34750035 10.1016/j.eururo.2021.10.001
156. Antonarakis ES Piulats JM Gross-Goupil M Goh J Ojamaa K Hoimes CJ Vaishampayan U Berger R Sezer A Alanko T de Wit R Li C Omlin A Procopio G Fukasawa S Tabata KI Park SH Feyerabend S Drake CG Wu H Qiu P Kim J Poehlein C Bono, Pembrolizumab for treatment-refractory metastatic castration-resistant prostate Cancer: Multicohort, open-label phase II KEYNOTE-199 study J Clin Oncol 2020 38 395 405 10.1200/JCO.19.01638 31774688
Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, Vaishampayan U, Berger R, Sezer A, Alanko T, de Wit R, Li C, Omlin A, Procopio G, Fukasawa S, Tabata KI, Park SH, Feyerabend S, Drake CG, Wu H, Qiu P, Kim J, Poehlein C. Bono, Pembrolizumab for treatment-refractory metastatic castration-resistant prostate Cancer: Multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2020;38:395–405. de.31774688 10.1200/JCO.19.01638
157. Peters S, Paz-Ares L, Herbst RS, Reck M. Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects. J Immunother Cancer, 10 (2022).
158. Dong J Miao J Miao Y Qu Z Zhang S Zhu P Wiede F Jassim BA Bai Y Nguyen Q Lin J Chen L Tiganis T Tao WA Zhang ZY Small molecule degraders of protein tyrosine phosphatase 1B and T-Cell protein tyrosine phosphatase for Cancer Immunotherapy Angew Chem Int Ed Engl 2023 62 e202303818 10.1002/anie.202303818 36973833
Dong J, Miao J, Miao Y, Qu Z, Zhang S, Zhu P, Wiede F, Jassim BA, Bai Y, Nguyen Q, Lin J, Chen L, Tiganis T, Tao WA, Zhang ZY. Small molecule degraders of protein tyrosine phosphatase 1B and T-Cell protein tyrosine phosphatase for Cancer Immunotherapy. Angew Chem Int Ed Engl. 2023;62:e202303818.36973833 10.1002/anie.202303818
159. O’Donnell JS Massi D Teng MWL Mandala M PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux Semin Cancer Biol 2018 48 91 103 10.1016/j.semcancer.2017.04.015 28467889
O’Donnell JS, Massi D, Teng MWL, Mandala M. PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. Semin Cancer Biol. 2018;48:91–103.28467889 10.1016/j.semcancer.2017.04.015
160. Ambrosini M Rousseau B Manca P Artz O Marabelle A Andre T Maddalena G Mazzoli G Intini R Cohen R Cercek A Segal NH Saltz L Varghese AM Yaeger R Nusrat M Goldberg Z Ku GY El Dika I Margalit O Grinshpun A Murtaza Kasi P Schilsky R Lutfi A Shacham-Shmueli E Khan Afghan M Weiss L Westphalen CB Conca V Decker B Randon G Elez E Fakih M Schrock AB Cremolini C Jayachandran P Overman MJ Lonardi S Pietrantonio F Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer Ann Oncol 2024 35 643 55 10.1016/j.annonc.2024.03.009 38777726
Ambrosini M, Rousseau B, Manca P, Artz O, Marabelle A, Andre T, Maddalena G, Mazzoli G, Intini R, Cohen R, Cercek A, Segal NH, Saltz L, Varghese AM, Yaeger R, Nusrat M, Goldberg Z, Ku GY, El Dika I, Margalit O, Grinshpun A, Murtaza Kasi P, Schilsky R, Lutfi A, Shacham-Shmueli E, Khan Afghan M, Weiss L, Westphalen CB, Conca V, Decker B, Randon G, Elez E, Fakih M, Schrock AB, Cremolini C, Jayachandran P, Overman MJ, Lonardi S, Pietrantonio F. Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer. Ann Oncol. 2024;35:643–55.38777726 10.1016/j.annonc.2024.03.009
161. Zhou Y Li A Yu H Wang Y Zhang X Qiu H Du W Luo L Fu S Zhang L Hong S Neoadjuvant-adjuvant vs neoadjuvant-only PD-1 and PD-L1 inhibitors for patients with Resectable NSCLC: an Indirect Meta-Analysis JAMA Netw Open 2024 7 e241285 10.1001/jamanetworkopen.2024.1285 38451524
Zhou Y, Li A, Yu H, Wang Y, Zhang X, Qiu H, Du W, Luo L, Fu S, Zhang L, Hong S. Neoadjuvant-adjuvant vs neoadjuvant-only PD-1 and PD-L1 inhibitors for patients with Resectable NSCLC: an Indirect Meta-Analysis. JAMA Netw Open. 2024;7:e241285.38451524 10.1001/jamanetworkopen.2024.1285
162. Galle P, Finn RS, Mitchell CR, Ndirangu K, Ramji Z, Redhead GS, Pinato DJ. Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review. J Immunother Cancer, 12 (2024).
163. Rowe JH Elia I Shahid O Gaudiano EF Sifnugel NE Johnson S Reynolds AG Fung ME Joshi S LaFleur MW Park JS Pauken KE Rabinowitz JD Freeman GJ Haigis MC Sharpe AH Formate supplementation enhances Antitumor CD8 + T-cell fitness and efficacy of PD-1 blockade Cancer Discov 2023 13 2566 83 10.1158/2159-8290.CD-22-1301 37728660
Rowe JH, Elia I, Shahid O, Gaudiano EF, Sifnugel NE, Johnson S, Reynolds AG, Fung ME, Joshi S, LaFleur MW, Park JS, Pauken KE, Rabinowitz JD, Freeman GJ, Haigis MC, Sharpe AH. Formate supplementation enhances Antitumor CD8 + T-cell fitness and efficacy of PD-1 blockade. Cancer Discov. 2023;13:2566–83.37728660 10.1158/2159-8290.CD-22-1301
164. Andreu-Saumell I Rodriguez-Garcia A Muhlgrabner V Gimenez-Alejandre M Marzal B Castellsague J Braso-Maristany F Calderon H Angelats L Colell S Nuding M Soria-Castellano M Barbao P Prat A Urbano-Ispizua A Huppa JB Guedan S CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition Nat Commun 2024 15 3552 10.1038/s41467-024-47799-z 38670972
Andreu-Saumell I, Rodriguez-Garcia A, Muhlgrabner V, Gimenez-Alejandre M, Marzal B, Castellsague J, Braso-Maristany F, Calderon H, Angelats L, Colell S, Nuding M, Soria-Castellano M, Barbao P, Prat A, Urbano-Ispizua A, Huppa JB, Guedan S. CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition. Nat Commun. 2024;15:3552.38670972 10.1038/s41467-024-47799-z
165. Fernandez-Barrena MG Arechederra M Colyn L Berasain C Avila MA Epigenetics in hepatocellular carcinoma development and therapy: the tip of the iceberg JHEP Rep 2020 2 100167 10.1016/j.jhepr.2020.100167 33134907
Fernandez-Barrena MG, Arechederra M, Colyn L, Berasain C, Avila MA. Epigenetics in hepatocellular carcinoma development and therapy: the tip of the iceberg. JHEP Rep. 2020;2:100167.33134907 10.1016/j.jhepr.2020.100167
166. Deutsch JS, Lai J, Schenk KM, Soni A, Will EM, Engle LL, Xu H, Ogurtsova A, Madan V, Chong JK, Wang D, Green BF, Nguyen P, Schollenberger MD, Lipson EJ, Taube JM. Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockade. J Immunother Cancer, 11 (2023).
167. Luke JJ Patel MR Blumenschein GR Hamilton E Chmielowski B Ulahannan SV Connolly RM Santa-Maria CA Wang J Bahadur SW Weickhardt A Asch AS Mallesara G Clingan P Dlugosz-Danecka M Tomaszewska-Kiecana M Pylypenko H Hamad N Kindler HL Sumrow BJ Kaminker P Chen FZ Zhang X Shah K Smith DH De Costa A Li J Li H Sun J Moore PA The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial Nat Med 2023 29 2814 24 10.1038/s41591-023-02593-0 37857711
Luke JJ, Patel MR, Blumenschein GR, Hamilton E, Chmielowski B, Ulahannan SV, Connolly RM, Santa-Maria CA, Wang J, Bahadur SW, Weickhardt A, Asch AS, Mallesara G, Clingan P, Dlugosz-Danecka M, Tomaszewska-Kiecana M, Pylypenko H, Hamad N, Kindler HL, Sumrow BJ, Kaminker P, Chen FZ, Zhang X, Shah K, Smith DH, De Costa A, Li J, Li H, Sun J, Moore PA. The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nat Med. 2023;29:2814–24.37857711 10.1038/s41591-023-02593-0
168. Mulholland M Kritikou E Katra P Nilsson J Bjorkbacka H Lichtman AH Rodriguez A Engelbertsen D LAG3 regulates T cell activation and plaque infiltration in atherosclerotic mice JACC CardioOncol 2022 4 635 45 10.1016/j.jaccao.2022.09.005 36636446
Mulholland M, Kritikou E, Katra P, Nilsson J, Bjorkbacka H, Lichtman AH, Rodriguez A, Engelbertsen D. LAG3 regulates T cell activation and plaque infiltration in atherosclerotic mice. JACC CardioOncol. 2022;4:635–45.36636446 10.1016/j.jaccao.2022.09.005
169. Kang JH Zappasodi R Modulating Treg stability to improve cancer immunotherapy Trends Cancer 2023 9 911 27 10.1016/j.trecan.2023.07.015 37598003
Kang JH, Zappasodi R. Modulating Treg stability to improve cancer immunotherapy. Trends Cancer. 2023;9:911–27.37598003 10.1016/j.trecan.2023.07.015
170. Vesely MD Zhang T Chen L Resistance mechanisms to Anti-PD Cancer Immunotherapy Annu Rev Immunol 2022 40 45 74 10.1146/annurev-immunol-070621-030155 35471840
Vesely MD, Zhang T, Chen L. Resistance mechanisms to Anti-PD Cancer Immunotherapy. Annu Rev Immunol. 2022;40:45–74.35471840 10.1146/annurev-immunol-070621-030155
171. Boyiadzis MM Kirkwood JM Marshall JL Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease j Immunotherapy cancer 2018 9 35 10.1186/s40425-018-0342-x
Boyiadzis MM, Kirkwood JM, Marshall JL, et al. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. j Immunotherapy cancer. 2018;9:35.10.1186/s40425-018-0342-x
